Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE

Subclass of:

435 - Chemistry: molecular biology and microbiology

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435375000 Method of regulating cell metabolism or physiology 594
435363000 Primate cell, per se 471
435395000 Solid support and method of culturing cells on said solid support 252
435352000 Rodent cell, per se 129
435378000 Method of detaching cells, digesting tissue or establishing a primary culture 84
435326000 Animal cell, per se, expressing immunoglobulin, antibody, or fragment thereof 80
435348000 Insect cell, per se 74
435374000 Method of storing cells in a viable state 64
435404000 Culture medium, per se 59
435383000 Method of culturing cells in suspension 59
435373000 Method of co-culturing cells 31
435349000 Avian cell, per se 21
435350000 Canine cell, per se 20
435346000 Fused or hybrid cell, per se 20
435347000 Two or more cell types, per se, in co-culture 19
435351000 Feline cell, per se 4
20100267131Feline Pancreatic Lipase - Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.10-21-2010
20090298168Method of genetically altering and producing allergy free cats - A transgenic cat with a phenotype characterized by the substantial absence of the major cat allergen, Fel d I. The phenotype is conferred in the transgenic cat by disrupting the coding sequence of the target gene with a specialized construct. The phenotype of the transgenic cat is transmissible to its offspring.12-03-2009
20120225479THERMOSTABLE VARIANTS OF FIBROBLAST GROWTH FACTORS - The present technology relates to engineered human Fibroblast Growth Factor-2 (FGF2) proteins and methods of using the same. In particular, the methods and compositions relate to FGF2 mutants with increased thermostability compared to the wild-type protein and method for using the proteins in the culturing of embryonic stem cells.09-06-2012
20110217773METHOD TO RESTORE CARTILAGINOUS PHENOTYPE OF CHONDROCYTES AFTER CULTURED AND EXPANDED IN VITRO - The present invention provides a method for restoring native chondrocyte phenotype and functions of, and/or increasing type II collagen as well as aggrecan mRNA expression levels and GAG accumulation level in dedifferentiated chondrocytes which have been subcultured and expanded in vitro, which comprising culturing the said dedifferentiated chondrocytes in vitro with a medium comprising type II collagen, or its biologically active peptide fragment(s) or analogs with or without growth factor(s), wherein the type II collagen or its biologically active peptide fragment(s) or analogs are effective to restore chondrocyte phenotype and functions of, and/or to increase type II collagen and aggrecan expression levels and GAG accumulation level in the said dedifferentiated chondrocytes.09-08-2011
435382000 Method of culturing encapsulated cells 2
20120225483Microsphere-Containing Cell Aggregate - The present invention relates to a microsphere-containing cell aggregate including: hydrogel microspheres being obtained by chemical cross-linking of one or more water-soluble synthetic macromolecules selected from the group consisting of water-soluble synthetic polymers, polysaccharides, and proteins; and cells. The present invention also relates to a method for producing the microsphere-containing cell aggregate.09-06-2012
20120301963COVERED MICRO GEL FIBER - A microfiber showing improved mechanical strength, which comprises a micro gel fiber consisting of collagen gel or the like covered with high strength hydrogel such as alginate gel.11-29-2012
Entries
DocumentTitleDate
20130040385HIV-1 LATENCY MODEL FOR HIGH THROUGHPUT SCREENING - Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.02-14-2013
20090269840Biological Products - There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.10-29-2009
20110183413Biologically active C-terminal arginine-containing peptides - The present invention concerns the separation, identification and characterization of active peptide fragments from peptones.07-28-2011
20090203124MAGE-A3 PEPTIDES PRESENTED BY HLA-DR1 MOLECULES - The invention describes HLA class II binding peptides encoded by the MAGE tumor associated genes, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD408-13-2009
20110195496MICROWELL ARRAY CHIP AND METHOD OF MANUFACTURING SAME - The present invention is directed to a microwell array chip made of silicon and having multiple microwells. Each microwell is used to store a single specimen organic cell. Each microwell is of a size and shape holding just one organic cell, and the interior surface of the microwells are coated with a fluorocarbon film.08-11-2011
20110195495Nucleic Acid Purification - The inventive self-contained apparatus for isolating nucleic acid, cell lysates and cell suspensions from unprocessed samples apparatus, to be used with an instrument, comprises at least one input, and: (i) a macrofluidic component, comprising a chamber for receiving said unprocessed sample from a collection device and at least one filled liquid purification reagent storage reservoir; and (ii) a microfluidic component in communication with said macrofluidic component via at least one microfluidic element, said microfluidic component further comprising at least one nucleic acid purification matrix; and (iii) a drive mechanism on said instrument for driving said liquid purification reagent, through said microfluidic element and said nucleic acid purification matrix, wherein the only inputs to said apparatus are via said chamber and said drive mechanism.08-11-2011
20110195494DLL4-BINGING MOLECULES - DII4-binding molecules, preferably DII4-binding immunoglobulin single variable domains like VHHs and VHs, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with DII4-mediated effects on angiogenesis. Bispecific DII4-binding molecules that also bind to VEGF-A. Nucleic acids encoding DII4-binding molecules, host cells and methods for preparing same.08-11-2011
20130210135RECOMBINANT VSV FOR THE TREATMENT OF TUMOR CELLS - The present invention relates to compositions and methods for the treatment of tumor and/or malignant and/or cancerous cells. The present invention provides VSV vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat shock protein gp96, or endostatin or angiostatin, wherein said VSV vectors exhibit greater oncolytic activity against the tumor and/or malignant and/or cancerous cell than a wild-type VSV vector. The present invention also provides methods of making such vectors, host cells, expression systems, and compositions comprising such VSV vectors, and viral particles comprising such VSV vectors. The present invention also provides methods for producing oncolytic activity in a tumor and/or malignant and/or cancerous cell comprising contacting said cell with a VSV vector of the present invention. The present invention also provides methods for suppressing tumor growth comprising contacting said tumor with a VSV vector of the present invention. The present invention also provides methods for eliciting an immune response to a tumor cell in an individual.08-15-2013
20100075412T1R TASTE RECEPTORS AND GENES ENCODING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T03-25-2010
20120244614METHOD FOR CULTURING MYCOPLASMA CONTAMINATION-FREE CELLS AND METHOD FOR REMOVING MYCOPLASMA CONTAMINATION OF CELLS - Provided is a method for culturing cells, which prevents the possibility of mycoplasma contamination by culturing the cells using biomass extract obtained by culturing a strain with amphidinol productivity, preferably a strain such as 09-27-2012
20130084634MICROFLUIDIC HANGING DROP CHIP - A microfluidic hanging drop chip is disclosed. Also disclosed are methods for culturing cells and forming cell aggregates in hanging drops.04-04-2013
20130034899CELL CULTURING DEVICE USING ELECTRICAL RESPONSIVENESS FUNCTIONAL MATERIAL, CELL CULTURING SYSTEM INCLUDING THE SAME, AND CELL CULTURING METHOD - A cell culturing device includes: an electrode on a surface of which a hydrophilicity/hydrophobicity converting material adapted to be electrically changed between hydrophilicity and hydrophobicity is provided. In this case, the electrode is disposed within a region in which a cell to be cultured is adapted to be accommodated. With the cell culturing device, the application of the suitable voltage to the electrode changes the hydrophilicity/the hydrophobicity of the hydrophilicity/hydrophobicity converting material. Thus, the feed material adsorbed to the hydrophilicity/hydrophobicity converting material is desorbed, thereby making it possible to feed the feed material to the cell.02-07-2013
20130040386GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES - The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.02-14-2013
20130210136Methods For Treating Cardio Pulmonary Diseases With NO Group Compounds - Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation comprises administering into the lungs as a gas a compound with an NO group which does not form NO08-15-2013
20090155896Human Cancer Suppressor Gene, Protein Encoded Therein, Expression Vector Containing The Same, And Cell Transformed By The Vector - Disclosed are a human cancer suppressor gene, a protein encoded therein, an expression vector containing the same, and a cell transformed by the vector. The gene of the present invention can be used for diagnosing, preventing and treating the human cancers.06-18-2009
20100041135Gastric Submucosal Tissue as a Novel Diagnostic Tool - A cell culture growth substrate comprising submucosal tissue of a warm-blooded vertebrate and a method for culturing fastidious organisms is described. Submucosal tissue used in accordance with the present invention supports the proliferation of cells when said cells are contacted with submucosal tissue under conditions conducive to cell proliferation.02-18-2010
20100041134SELF-ASSEMBLING MULTICELLULAR BODIES AND METHODS OF PRODUCING A THREE-DIMENSIONAL BIOLOGICAL STRUCTURE USING THE SAME - Structures and methods for tissue engineering include a multicellular body including a plurality of living cells. A plurality of multicellular bodies can be arranged in a pattern and allowed to fuse to form an engineered tissue. The arrangement can include filler bodies including a biocompatible material that resists migration and ingrowth of cells from the multicellular bodies and that is resistant to adherence of cells to it. Three-dimensional constructs can be assembled by printing or otherwise stacking the multicellular bodies and filler bodies such that there is direct contact between adjoining multicellular bodies, suitably along a contact area that has a substantial length. The direct contact between the multicellular bodies promotes efficient and reliable fusion. The increased contact area between adjoining multicellular bodies also promotes efficient and reliable fusion. Methods of producing multicellular bodies having characteristics that facilitate assembly of the three-dimensional constructs are also provided.02-18-2010
20100041133Biological targeting compositions and methods of using the same - Modified red blood cells are described. In an embodiment, the modified red blood cell includes a target-binding agent. Targeted delivery of imaging agents, drugs, and peptide and protein pharmaceuticals using modified red blood cells are described. Processes for preparing the modified red blood cells, pharmaceutical and diagnostic compositions containing the same and methods of diagnosis and treatment involving the modified red blood cells are described.02-18-2010
20100041132Bioreactor System - In one aspect the invention provides a bioreactor system for the production of tissue prostheses. The system includes a bioreactor, a culture medium reservoir coupled to the bioreactor by a first conduit and a second conduit, a pump operable to pump fluid into and draw fluid out of a pumping chamber defined in the bioreactor to generate a pulsatile flow of culture medium through the reservoir and bioreactor via said first and second conduits, one or more flow meters operable to generate flow rate signals representative of the rate of culture medium flow through one or both of said first and second conduits, and a controller arranged to receive said flow rate signals from said one or more flow meters and to control the pump means in response to said received flow rate signals to provide a desired rate of culture medium flow.02-18-2010
20120214230CELL CULTURE/HANDLING PRODUCT AND METHOD FOR PRODUCTION AND USE THEREOF - The present invention relates to a fast a simple coating procedure for coating of cell culture and/or handling surfaces to prevent cell adhesion and growth. The invention relates to a cell culture/handling product coated with phenyl dextran, as well as methods of producing and using it.08-23-2012
20100330670Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes - The invention provides methods for depleting extraneous phenotypes from a mixed population of cells comprising the in vitro differentiated progeny of primate pluripotent stem cells. The invention also provides mixed cell populations enriched for a target cell phenotype where the mixed cell population comprises the differentiated in vitro progeny of primate embryonic stem cells.12-30-2010
20130029411SYSTEMS, METHODS AND CONTROL LAWS FOR CELL HARVESTING - The methods of harvesting cells are provided, wherein the methods comprise introducing a processing material and a source material into a processing loop. The processing loop comprises a processing chamber and a filtering device. The processing material and the source material are circulating through the processing chamber and the filtering device, wherein the processing chamber has a mass; balancing an influx of the processing material into the processing chamber with a permeate flux of the filtering device to maintain the mass of the processing chamber at a constant value; and collecting the cells in a collection chamber. Cell harvesting devices are also provided for processing and harvesting cells using a control law to balance the mass of the processing chamber through the entire process.01-31-2013
20130029412CELL CULTURE SYSTEM - A microtiter plate based cell culture system comprising an improved cell culture insert which is suitable and used for the cultivation of adherent cells and/or three-dimensional tissues.01-31-2013
20100093079Automated Tissue Staining System And Reagent Container - An automated staining system and a reagent container designed for use with the automated staining apparatus. The reagent container includes a reagent containment section capable of containing a volume of a reagent. The reagent containment section includes an upper wall and a base wall that are spaced apart along an axis. The base wall includes a well having a nadir that is aligned axially with an access opening in the upper wall so that a reagent probe entering the opening parallel to said axis will travel toward the nadir. In another aspect of the invention, the reagent container may include a two-dimensional data element containing reagent information. The staining apparatus may include one removable drawer for holding reagent containers and another removable drawer holding slides.04-15-2010
20080206860Vessel and Culture System Including - A vessel includes a gas reservoir. The vessel also includes at least one gas outlet. The gas outlet includes an integral gas permeable membrane. A culture system includes the vessel as a first vessel. The first vessel is coupled to a second vessel that includes or otherwise contains a cell, a plant, an animal or the like. 08-28-2008
20120107927METHODS AND DEVICES FOR ISOLATING EMBRYONIC STEM CELLS - Methods, devices and kits are provided for isolating or enriching multicellular embryonic stem (ES) cell colonies from a mixture of multicellular ES cell colonies and single ES cells present in a cellular suspension, by utilizing a filtration matrix that selectively excludes passage of multicellular ES cell colonies. Isolated or enriched multicellular ES cell colonies can be used for propagating pluripotent ES cells.05-03-2012
20100068802NOVEL HUMAN ANDROGEN RECEPTOR ALTERNATIVE SPLICE VARIANTS AS BIOMARKERS AND THERAPEUTIC TARGETS - The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.03-18-2010
20090042283OPTIMIZED MESSENGER RNA - The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.02-12-2009
20110003380Sample Processing System and Methods - The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder (01-06-2011
20090305401PLASMA-FREE PLATELET LYSATE FOR USE AS A SUPPLEMENT IN CELL CULTURES AND FOR THE PREPARATION OF CELL THERAPEUTICS - The present invention provides a cell culture medium supplement comprising plasma-free platelet lysate and medium supplemented with this supplement. The present invention further provides a method for preparing the supplement comprising the steps of (a) preparing platelet rich plasma; (b) removing the plasma; and (c) lysing the platelets.12-10-2009
20090305400Modified chaperonin 10 - A novel granule dispersion composition which comprises water and, dispersed therein, a finely pulverized, sparingly water-soluble substance. The granule dispersion composition is prepared by dispersing in water a granular material which comprises a specific substance sparingly soluble in water, a polymer, and an oil and has an average particle diameter of 1 μm or smaller and in which the ratio of the total weight of the polymer and oil to the weight of the specific substance is 1.5 or higher.12-10-2009
20090305399DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression - Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.12-10-2009
20130071919METHOD OF SELECTING INDUCED PLURIPOTENT STEM CELL - The present invention provides a method of selecting a highly safe induced pluripotent stem cell, which includes comprehensively detecting the sequence of an expression vector used for induction of the induced pluripotent stem cell, in the nucleic acid in the cell, and a kit used for the method.03-21-2013
20130071920Mesenchymal Stem Cell Attractant and Method for Attracting Mesenchymal Stem Cell - The present invention aims to provide a mesenchymal stem cell attractant capable of attracting a mesenchymal stem cell; and others. The present invention provides a mesenchymal stem cell attractant containing at least one selected from the group consisting of an extract of a 03-21-2013
20120220028ENHANCER FOR PROMOTER, AND USE THEREOF - Disclosed is an enhancer for a viral promoter such as a promoter that can induce expression selectively and strongly in immunocompetent cells (e.g., lymphocytes) or blood cells. It is found unexpectedly that an intron has the above-mentioned enhancer activity. Thus, it is found that an enhancer for a promoter, which comprises an intron sequence for a major immediate early gene (MIE) of human herpes virus-6 (HHV-6) (particularly HHV-6B) or a fragment of the intron sequence, has a potent promoter activity.08-30-2012
20090093050DNA Vaccine Enhancement with MHC Class II Activators - Methods for treating or preventing hyperproliferating diseases, e.g., cancer, are described. A method may comprise administering to a subject in need thereof a therapeutically effective amount of a nucleic acid encoding an MHC class I and/or II activator and optionally a nucleic acid encoding an antigen.04-09-2009
20130059373ENDOMETRIAL POLYP STEM CELL - An endometrial polyp stem cell is disclosed in the present invention. The endometrial polyp stem cell is isolated from an endometrial polyp tissue, expresses vimentin, CD13, CD29, CD44, and CD90, and has no expression of CD1q, CD3, CD34, and CD45.03-07-2013
20090203122Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof - Cloning, expression, viral and delivery vectors and hosts which contain nucleic acid coding for at least one peripheral nervous system specific (PNS) sodium channel peptide (SCP), isolated PNS SCP, and compounds and compositions and methods, are provided, for isolating, crystallizing, x-ray analysing molecular modeling, rational drug designing, selecting, making and using therapeutic or diagnostic agents or ligands having at least one peripheral nervous system specific (PNS) sodium channel (SC) modulating activity.08-13-2009
20090269842TRANSMEMBRANE DELIVERY PEPTIDE AND BIO-MATERIAL COMPRISING THE SAME - The present invention relates to a transmembrane delivery peptide derived from human in which a target protein may be easily delivered into cells, and a recombinant vector comprising a nucleic acid coding the peptide. More specifically, the present invention relates to the transmembrane delivery peptide having an amino acid sequence described in SEQ ID No. 1 including 11 amino acids of specific sites in amino acid sequences of human G protein alpha 12, and a recombinant vector comprising a nucleic acid coding the same, a transformant prepared by introducing said recombinant vector, and the like. Since transmembrane delivery peptides of the present invention can be efficiently delivered into cells, they may be usefully used for the purposes of delivering various target materials, including proteins, nucleic acid, drugs and the like.10-29-2009
20090269841METHOD AND SYSTEM FOR THE PRODUCTION OF CELLS AND CELL PRODUCTS AND APPLICATIONS THEREOF - A cell culture system for the production of cells and cell derived products includes a reusable instrumentation base device incorporating hardware to support cell culture growth. A disposable cultureware module including a cell growth chamber is removably attachable to the instrumentation base device. The base device includes microprocessor control and a pump for circulating cell culture medium through the cell growth chamber. The cultureware module is removably attached to the instrumentation base device. Cells are introduced into the cell growth chamber and a source of medium is fluidly attached to the cultureware module. Operating parameters are programmed into the microprocessor control. The pump is operated to circulate the medium through the cell growth chamber to grow cells or cell products therein. The grown cells or cell products are harvested from the cell growth chamber and the cultureware module is then disposed.10-29-2009
20130065298siRNA-MEDIATED GENE SILENCING - The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules.03-14-2013
20090233354MULTIPOTENT ADULT STEM CELLS AND METHODS FOR ISOLATION - The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.09-17-2009
20090233353MULTIPOTENT ADULT STEM CELLS AND METHODS FOR ISOLATION - The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.09-17-2009
20120115221SPARC-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES AND MEDICAMENTS COMPRISING THE SAME - It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: 05-10-2012
20090011498EXPANSION OF NK CELLS AND THERAPEUTIC USES THEREOF - The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells.01-08-2009
20090011497Peptides and related compounds having thrombopoietic activity - The present invention relates generally to novel peptides and related compounds that have thrombopoietic activity. The compounds of the invention may be used to increase production of platelets or platelet precursors (e.g. megakaryocytes) in a mammal.01-08-2009
20120238012CYTOTOXIC T LYMPHOCYTE - The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte.09-20-2012
20110065177Novel Collectin - Novel collectin related molecules i.e., a novel collectin gene comprising a nucleotide sequence set out in SEQ ID NO: 1, and a novel collectin comprising an amino acid sequence set out in SEQ ID NO: 2, which are expected to exhibit anti-bacterial, anti-viral activity or the like especially in human body, and methods in which these molecules are used are provided.03-17-2011
20120129251METHOD FOR DEPARAFFINIZING FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE - The invention provides a method for deparaffinizing a formalin-fixed paraffin-embedded tissue, including: providing a formalin-fixed paraffin-embedded tissue sample; mixing the formalin-fixed paraffin-embedded tissue sample with an organic solvent and water or with an organic solvent and an aqueous solution to form a mixture, wherein a density of the organic solvent is less than that of the water or the aqueous solution, and the organic solvent is immiscible with the water or the aqueous solution; and separating the mixture into an organic solution layer and an aqueous solution layer, wherein a paraffin dissolved from the formalin-fixed paraffin-embedded tissue sample is in the organic solution layer and a deparaffinized tissue from the formalin-fixed paraffin-embedded tissue sample is in the aqueous solution layer and/or an interlayer between the organic solution layer and the aqueous solution layer.05-24-2012
20090042284Method for labeling/separation of cells and agent for labeling/separation of cells - Disclosed are a cell labeling/separation method and a cell labeling/separation agent capable of identifying a target cell in a simplified manner while achieving a significantly high degree of accuracy in cell separation. The method comprises adding a micro- or nano-capsule 02-12-2009
20130011917METHOD OF GENERATING MYELINATING OLIGODENDROCYTES - A method of differentiating embryonic stem cells into oligodendroglial precursor cells and oligodendroglial cells by culturing a population of cells comprising a majority of cells that are characterized by a neural tube-like rosette morphology and are Pax6+/Sox1+ into a population of cells that are PDGFRα+.01-10-2013
20110070641Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations - Enriched pancreatic stem and progenitor cell populations, and methods for identifying, isolating, and enriching for pancreatic stem cells using reagents that bind to cell surface markers are provided.03-24-2011
20100167393MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN - Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.07-01-2010
20110003381VIRAL VECTORS AND HOST CELLS AND METHODS OF MAKING AND USING THEM - The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating, selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, and methods of using such a vector and a host cell.01-06-2011
20100267130Chlamydomonas Intraflagellar Transport 88 (IFT-88) - The invention relates to various intraflagellar transport (IFT) polypeptides and the nucleic acids that encode them. The new IFT particle polypeptides and nucleic acids can be used in a variety, of diagnostic, screening, and therapeutic methods.10-21-2010
20090124003MODULATORS OF ODORANT RECEPTORS - The present invention relates to polypeptides capable of promoting odorant receptor cell surface localization and odorant receptor functional expression. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for odorant receptor accessory protein polymorphisms and mutations associated with disease states, as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.05-14-2009
20100144030Method and Apparatus for Gender Selection Based on pH - The present invention includes methods and apparatus to separate X or Y-chromosome bearing sperm cells in a population by first placing the population of sperm cells at physiological pH environment, and simultaneously contacting the population of sperm cells with one or more additional sub-environments with different pH values. The exposure allows mobile sperm cells bearing X or Y-chromosome to migrate to the different pH sub-environments, wherein each cell only exposed or come in contact with one pH sub-environment. Finally, the collecting X or Y-chromosome enriched population of sperm cells is performed.06-10-2010
20110300625TISSUE FOR PROSTHETIC IMPLANTS AND GRAFTS, AND METHODS ASSOCIATED THEREWITH - A prepared tissue for medical use with a patient is provided. Methods for preparing such tissue are also provided. Implantable tissue is provided by harvesting a tissue, such as but not limited to a pericardium tissue, and exposing the tissue to various cleaning, rinsing, treatment, separating, and fixation steps. The tissue of at least one embodiment is cleaned with distilled water, rinsed with isopropyl alcohol, and treated with a glutaraldehyde solution. The prepared tissue may be allowed to dry or partially hydrated prior to packaging and shipment. As such, the tissue can be implanted into the receiving patient in either a dry or wet state. The relatively thin yet strong tissue material is adapted for implanting within or grafting to human tissue. By way of example, the tissue may be used in a shunt, a valve, as graft material, as a patch, as a prosthetic tissue in a tendon and/or ligament, and a tissue product for wound management.12-08-2011
20110136223NEURTURIN RECEPTOR - NTNRα, NTNRα extracellular domain (ECD), NTNRα variants, chimeric NTNRα (e.g., NTNRα immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNRα-ligands, for example NTN, by providing NTNRα to the cell.06-09-2011
20110124103MACROCYCLIC DERIVATIVE AND ASSEMBLIES FORMED THEREFROM - The present invention is directed to a macrocyclic derivative which is formed by modification of a macrocycle. The invention further relates to assemblies formed by the self-assembly of such macrocyclic derivatives in aqueous solvent, and includes bilayer vesicles, micelles, monolayers, nanoparticles, colloidal assemblies and surface-coated assemblies.05-26-2011
20120107926APPARATUS FOR CELL OR TISSUE CULTURE - The apparatus for cell or tissue culture comprises a base plate (05-03-2012
20120107924COMPOSITIONS AND METHODS FOR MODIFYING CELL SURFACE GLYCANS - Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.05-03-2012
20120009669BIFUNCTIONAL COMPOUND WITH MONOSACCHARIDE AND N2S2 LIGAND, AND PREPARATION AND USE THEREOF - A bifunctional compound with a monosaccharide and a N01-12-2012
20110143431Method Of Preparing An Undifferentiated Cell - Disclosed is a method of preparing an undifferentiated cell. The method includes contacting a more committed cell with an agent that causes the more committed cell to retrodifferentiate into an undifferentiated cell.06-16-2011
20110294206METHODS AND DESIGN OF MEMBRANE FILTERS - The present invention provides methods for designing a filtration systems for capturing viable tumor cells, such as circulating tumor cells at high efficiency and high viability. The methods involve development of a set of “key engineering design parameters” that are crucial to achieve high tumor cell viability. These important design parameters include the filter geometry design, fluid delivery method, drive pressure and filtration time.12-01-2011
20110294205AUTOMATED CELLULAR MATERIAL PREPARATION - Provided are cartridges and systems for effecting automated extraction, isolation, and purification of cellular components—such as nucleic acids—from a cellular sample in assay-ready form. Also provided are related methods of effecting such sample processing.12-01-2011
20100136681CELLULAR COMPOSITIONS FOR THE TREATMENT OF KIDNEY DISEASE AND USES THEREOF - As described in more detail below, the present invention provides cellular compositions for the treatment or prevention of kidney disease. The invention is based, at least in part, on the discovery of a population of cortical peritubular Flk1- and Seal-expressing kidney cells having a high tubulogenic potential.06-03-2010
20110217768NOVEL LIPASE - The present invention provides a novel lipase with a molecular weight of about 32 kDa, which is produced by a strain belonging to the genus Tetrasphaera, as well as a gene encoding the same. This lipase has the ability to recognize a medium-chain fatty acid as a substrate. The present invention also provides a novel lipase with a molecular weight of about 40 kDa, which is produced by a strain belonging to the genus 09-08-2011
20110217771Fluidic Culture Device - A fluidic culture device (09-08-2011
20110217770Cell Piercing Device and Method of Using Same - A cell piercing device comprising a container, a respectively matching cap and a cell interacting surface is disclosed. The cell interacting surface comprises a plurality of extensions or prongs. The cell piercing device may further comprise a pedestal. Furthermore, a method of facilitating an interaction with the interior of cells is disclosed. The method includes the steps of loading into the container of the cell piercing device, a liquid solution containing the cells and tightening the respectively matching cap. Then centrifuging the device while the extensions or prongs protruding from the cell interacting surface are oriented essentially within the direction of the vector of the centripetal force and thereafter centrifuging the device while said extensions or prongs are oriented essentially within the direction of the vector of the centrifugal force.09-08-2011
20110217767Single-use Stationary Bioreactors and Mixing Vessels - Stationary bioreactors and mixing vessels fitted with single-use flexible bags utilizing wave hydrodynamic principle are described for use in every type of biological process and products.09-08-2011
20090098648HIGH-TITER RETROVIRAL PACKAGING CELLS - The present invention relates to non-replicative recombinant retrovirus packaging cells able to grow in suspension in a serum-free medium. In particular, the present invention relates to a human embryonic 293SF-based cell line stably expressing gag and pol gene products from the murine Moloney leukemia virus (MLV) and either the feline RD114 env gene, the gibbon ape leukemia virus (GLV) env gene, or the amphotropic 4070Aenv gene. This particular combination allows the production of high titer of non-replicative retrovirus pseudotyped and prevents the recombination of plasmids. The recombinant retroviruses produced from these cells are safer and easier to produce for clinical use in gene therapy.04-16-2009
20080311652MAGE-C2 antigenic peptides and uses thereof - This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, β12-18-2008
20090317905MUTATIONS IN ION CHANNEL PROTEINS ASSOCIATED WITH SUDDEN CARDIAC DEATH - Previously unknown mutations of the KCNH2, SCN5A and KCNQ1 genes are disclosed which are involved in ion channel disruptions associated with short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease. These mutations are utilized to diagnose and screen for short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease, thus providing modalities for diagnosing sudden cardiac death and/or predicting susceptibility to sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant proteins described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.12-24-2009
20100035339HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR - The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.02-11-2010
20090148939NOVEL FLUORESCENT PROTEINS FROM AEQUOREA COERULSCENS AND METHODS FOR USING SAME - The present invention provides nucleic acid compositions encoding a novel colorless GFP-like protein, acGFP, from 06-11-2009
20090081779TUMOR SUPPRESSOR GENE, P28ING5 - This disclosure provides a novel tumor suppressor, referred to as p28ING5, nucleic acid molecules encoding this protein, and methods of making and using these molecules. Also provided are methods of ameliorating, treating, detecting, prognosing, and diagnosing diseases and conditions associated with abnormal p28ING5 expression, such as neoplasia. Kits are also provided.03-26-2009
20090068732Directed evolution methods for improving polypeptide folding and solubility and superfolder fluorescent proteins generated thereby - The current invention provides methods of improving folding of polypeptides using a poorly folding domain as a component of a fusion protein comprising the poorly folding domain and a polypeptide of interest to be improved. The invention also provides novel green fluorescent proteins (GFPs) and red fluorescent proteins that have enhanced folding properties.03-12-2009
20090148941Disposable mini-bioreactor device and method - This invention provides cylindrical cell culture tubes with a cap having both a septum and gas exchange membranes. The culture tubes can be used to inoculate media, culture cells, harvest cells and store cells in the same container with reduced risk of contamination, while facilitating automated handling.06-11-2009
20090148938Method for identifying ester coolers - The Transient Receptor Potential Cation Channel, Subfamily A, Member 1 (TRPA1) protein has been identified as an ester cooler receptor and therefore is useful in screening assays for identifying ester coolers, in particular ester coolers with a relative cooling strength which exceeds (−)−menthol.06-11-2009
20100120141Screening methods for compounds that modulate the activity of G-protein coupled receptors - The present invention relates to a screening system for modulators of GPCRs. Further it relates to recombinant vector systems for the heterologous expression of heterodimeric g-protein coupled receptors (GPCRs) in eucaryotic host cells. Preferably the functional expression of engineered GPCRs for the perception of sweet and L-amino acid taste or more preferably the use of said receptors for the identification of functional ligands is also encompassed.05-13-2010
20100267129CHIMERIC NUCLEIC ACIDS ENCODING POLYPEPTIDES COMPRISING DOMAINS OF TNF FAMILY LIGANDS - This invention relates to genes which encode accessory molecule ligands and their use for immunomodulation, vaccination and treatments of various human diseases, including malignancies and autoimmune diseases. This invention also describes the use of accessory molecule ligands which are made up of various domains and subdomain portions of molecules derived from the tumor necrosis factor family. The chimeric molecules of this invention contain unique properties which lead to the stabilization of their activities and thus greater usefulness in the treatment of diseases. Vectors for expressing genes which encode the accessory molecule ligands of this invention are also disclosed.10-21-2010
20100190245METHOD TO INCREASE DISSOLVED OXYGEN IN A CULTURE VESSEL - Basing on study of a previous discovered effective bioreactor system, a method to increase culture medium dissolved oxygen is disclosed. This method together with addition of an optimal mixing forms a theoretical foundation for effective bioreactor design and prototype construction.07-29-2010
20110177590Bioprinted Nanoparticles and Methods of Use - The present invention provides compositions and methods that combine the initial patterning capabilities of a direct cell printing system with the active patterning capabilities of magnetically labeled cells, such as cells labeled with superparamagnetic nanoparticles. The present invention allows for the biofabrication of a complex three-dimensional tissue scaffold comprising bioactive factors and magnetically labeled cells, which can be further manipulated after initial patterning, as well as monitored over time, and repositioned as desired, within the tissue engineering construct.07-21-2011
20120149099DIFFERENTIATION PROCESS OF MESENCHYMAL STEM CELLS AND THERAPEUTIC USE THEREOF - Process for inducing differentiation of mesenchymal stamina cells into neuroblasts and/or neurons that envisions the use of a differentiation solution consisting of retinoic acid and ethanol.06-14-2012
20120142089METHOD OF SEPARATING TARGET CELL IN BIOLOGICAL SAMPLE - Provided is a method of separating a target cell in a biological sample. A target cell may be efficiently separated from a biological sample including at least a second cell of similar density to the target cell using the disclosed method of separating a target cell in a biological sample according embodiment.06-07-2012
20100086996GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES - The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.04-08-2010
20120107925DEVICES FOR SEPARATING CELLS AND METHODS OF USING THEM - The present invention refers to a device for separating cells of a defined size from a sample and to a system comprising such devices and further components. Such devices can comprise different components, such as inlet module, intermediate module, outlet module and microsieve. The present invention also refers to methods of operating such devices and uses thereof.05-03-2012
20130217116Peptide II - There is provided an MHC class II peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the minimal epitope from the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) a minimal epitope from the region 281-420 of 5T4. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.08-22-2013
20100099182SYSTEM FOR MONITORING THE LOCATION OF TRANSGENES - A novel strategy for monitoring the location of a transgene in a mammal is disclosed. A sodium iodide symporter is genetically fused to either the N-terminus or C-terminus of the product of a transgene through a linker peptide which bears the recognition sequence of a host cell protease. Expression of the transgene confers the activity of the sodium iodide symporter (NIS) to a host cell which expresses the transgene. Subsequent administration of labeled iodine results in transport of the labeled iodine into the cell bearing the NIS, which can then be localized and measured using standard imaging techniques. The system is particularly useful for monitoring the location of therapeutic transgenes and tissue-specific distribution of the therapeutic gene product.04-22-2010
20090137033NOVEL FLUORESCENT PROTEINS FROM AEQUOREA COERULSCENS AND METHODS FOR USING SAME - The present invention provides nucleic acid compositions encoding a novel colorless GFP-like protein, acGFP, from 05-28-2009
20110201108ISOLATED MYELOID-LIKE BONE MARROW CELL POPULATIONS AND METHODS OF TREATMENT THEREWITH - The present invention provides an isolated myeloid-like bone marrow cell population comprising a majority of cells that are lineage negative, and which express both CD44 antigen and CD11b antigen. These cells have beneficial vasculotrophic and neurotrophic activity when intraocularly administered to the eye of a mammal, particularly a mammal suffering from an ocular degenerative disease. The myeloid-like bone marrow cells are isolated by treating bone marrow cells with an antibody against CD44 (hyaluronic acid receptor), against CD11b, or against both and using flow cytometry to positively select CD44 and/or CD11b expressing cells therefrom. The isolated myeloid-like bone marrow cells of the invention can be transfected with a gene encoding a therapeutically useful protein, for delivering the gene to the retina.08-18-2011
20110201107Multimodality imaging of reporter gene expression using a novel fusion vector in living cells and animals - Novel double and triple fusion reporter gene constructs harboring distinct imagable reporter genes are provided, as well as applications for the use of such double and triple fusion constructs in living cells and in living animals using distinct imaging technologies.08-18-2011
20110201106DEVICES AND METHODS FOR TISSUE HANDLING AND EMBEDDING - A mould and tissue cassette for automated embedding of tissue, and a method of operation are disclosed. The mould attaches to the cassette prior to embedding, and fits into a rack. The rack supports the mould holding the tissue cassette when the mould and cassette are in a first position. When the mould and cassette are moved to a second position, a projection on the rack separates the mould from the cassette, to facilitate easy removal. Also disclosed is a mould for a tissue cassette having projections for holding the mould to a rack, so that the tissue cassette is not in contact with the mould.08-18-2011
20110201105LACTATION-ASSOCIATED POLYPEPTIDES - The invention relates to cDNA libraries obtained from Tammar wallaby (08-18-2011
20110201104ANTIVIRAL AGENT AGAINST ANIMAL VIRUSES - Disclosed herein is an antiviral agent against animal viruses. The antiviral agent contains a protein or a nucleic acid sequence encoding the protein, as an active ingredient, the protein having binding ability and degrading ability to foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself. Disclosed herein is further an antiviral animal cell containing the protein according to the present invention, or the nucleic acid sequence encoding the protein. The antiviral agent and antiviral animal cell exhibit advantageous effects in that they selectively degrade foreign nucleic acid chains invaded in an animal cell and have no cytotoxicity to the animal cell, thus causing no death of the animal cell.08-18-2011
20110171727COMPOSITIONS AND METHODS FOR ACTIVATING GENES OF INTEREST - Compositions and methods for activating genes of interest are provided. The compositions comprise a masked targeted expression cassette which expresses a gene product only in the presence of a target molecule. The cassettes are useful for the treatment of disease and for preventing the proliferation of neoplastic cells.07-14-2011
20110171726MULTIPOTENT STEM CELLS DERIVED FROM HUMAN ADIPOSE TISSUE AND CELLULAR THERAPEUTIC AGENTS COMPRISING THE SAME - Human adipose tissue-derived multipotent adult stem cells are provided, which are characterized by the ability to be maintained in an undifferentiated state for a long period of time by forming spheres and which have high proliferation rates. Also provided are methods for isolating and maintaining the adult stem cells, and methods for differentiating the multipotent adult stem cells into nerve cells, fat cells, cartilage cells, osteogenic cells, muscle cells, endothelial cells, hepatic cells and insulin-releasing pancreatic β-cells. Also provided are cellular therapeutic agents for treating osteoarthritis, osteoporosis, nerve disease, diabetes and for forming breast tissue, which contain differentiated cells or the adult stem cells.07-14-2011
20090275125Human T1R2 Taste Receptor Nucleic Acids and Cells Containing These Nucleic Acids - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.11-05-2009
20090275124Methods and Compositions Comprising Anti-Idiotypic Antibodies to Anti-MMP-14 Antibodies - Provided are anti-idiotypic antibodies specific for a CDR of an anti-MMP-14 antibody for use as reagents in novel assays for anti-MMP-14 antibodies, pharmaceutical compositions and vaccines.11-05-2009
20110269226Microfluidic Continuous Flow Device for Culturing Biological Material - The present invention refers to a microfluidic continuous flow devices for culturing biological material each comprising a cultivation chamber being dimensioned to retain a biological material and having an inlet and an outlet to allow flow of a cultivation medium through the cultivation chamber. The present invention also refers to a method using the microfluidic continuous flow device of the present invention and the uses for these devices. In one example a microfluidic continuous flow device of the present invention is connected to a gradient generator.11-03-2011
20090286313NON-STEROIDAL ANTI-INFLAMMATORY DRUG ACTIVATED GENE WITH ANTI-TUMORIGENIC PROPERTIES - The present invention provides methods and compositions for drug screens to identify and characterize agents that are agonistic or antagonistic to activation of the promoter region of the NAG-1 gene. Activation of the NAG-1 gene is associated with the apoptotic elimination of cancer cells both in vitro and in vivo. The invention also provides novel promoter region sequences of the NAG-1 gene.11-19-2009
20090275123MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.11-05-2009
20090280562MATERIALS AND METHODS FOR PREPARING DIMERIC GROWTH FACTORS - Proteins consisting of, from amino to carboxyl terminus, a first PDGF-D growth factor domain polypeptide, a linker polypeptide, and a second PDGF-D growth factor domain polypeptide, and materials and methods for making the proteins are disclosed. Each of the first and second PDGF-D growth factor domain polypeptides consists of a sequence of amino acid residues as shown in SEQ ID NO:2 or SEQ ID NO:4 from amino acid x to amino acid y, wherein x is an integer from 246 to 258, inclusive, and y is an integer from 365-370, inclusive. The linker polypeptide consists of from 11-40 amino acid residues. The proteins can be used to stimulate the production of bone and/or connective tissue in both humans and non-human animals.11-12-2009
20090280561FUSION PROTEIN OF HIV REGULATORY/ACCESSORY PROTEINS - The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections.11-12-2009
20090286312Methods and Compositions for Treating Allergic Diseases - Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.11-19-2009
20090291492METHOD FOR FORMING ORGAN - A method for forming an organ and/or tissue from undifferentiated cells derived from a vertebrate animal in vitro, which comprises the step of culturing the undifferentiated cells derived from a vertebrate animal in the presence of a retinoic acid X receptor ligand (e.g., a retinoic acid X receptor agonist or antagonist), and a method for forming a pancreas from undifferentiated cells derived from a vertebrate animal in vitro or a method for forming a tissue having morphology and function of a pancreas from undifferentiated cells derived from a vertebrate in vitro, which comprises the step of culturing the undifferentiated cells derived from a vertebrate animal in the presence of a retinoic acid receptor ligand, together with activin, that does not substantially bind to the retinoic acid receptor subtype γ.11-26-2009
20100279398INSTRUMENT AND METHOD FOR TREATING MINOR AMOUNT OF BIOLOGICAL MATERIAL - Provided is a technique for handling a minor amount of a biological material with the purpose of observing selectively the interaction between single cells by controlling cell number and two- or three-dimensional configurations of each of the different cell types. The present invention provides an instrument and a method for handling a minor amount of a biological material. The instrument of the present invention for handling a minor amount of a biological material comprises a construct and a base, wherein: the base holds the construct in a releasable manner; the construct is held on a surface of the base in such a manner that a part of the construct is exposed externally on the outer face of the instrument; and at least a part of a surface of the constructs is exposed externally on the outer face of the instrument being fabricated so as to allow the adhesion of the minor amount of the biological material thereto.11-04-2010
20090148937MICRO-FLUIDIC SYSTEM COMPRISING AN EXPANDED CHANNEL - The invention relates to a micro-fluidic system including a fluid medium channel that holds a fluid medium containing particles in suspension. According to the invention, the fluid medium channel has an expanded section with an enlarged cross-section along part of its length, in order to reduce the flow speed to allow the analysis of the particles.06-11-2009
20110269227PEPTIDE HAVING BINDABILITY WITH ADIPONECTIN, ANALYSIS METHOD UTILIZING SAME PEPTIDE, AND ANALYSIS DEVICE UTILIZING SAME PEPTIDE - Developed is an adiponectin-recognition material which is inexpensive and excellent in: productivity; stability of quality and a structure; and convenience. The present invention provides a peptide consisting of not more than 50 amino acids and having bindability with adiponectin.11-03-2011
20100216233ATTENUATED INVASIVE E.COLI STRAINS AND APPLICATIONS THEREOF AS INTRACELLULAR VECTOR FOR THERAPEUTIC MOLECULE - The invention relates to a vectorial system capable of delivering a nucleic acid of interest into eukaryotic target cells, said vectorial system including a recombinant non-pathogenic and non-replicative 08-26-2010
20080241918Hemagglutinin polypeptides, and reagents and methods relating thereto - The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.10-02-2008
20080206862HIGH SURFACE CULTIVATION SYSTEM BAG - An exemplary embodiment of a reversibly closable bag suitable for the cultivation of cells and/or tissues can be provided. The exemplary bag can comprise at least one reversibly closable aperture in the bag wall, and a surface-increasing convection arrangement inside the bag. The convection arrangement is capable to generate and/or modify a convection in a fluid within said bag when at least one of the fluid, the bag, and the convection arrangement is agitated. For example, the surface increasing convection arrangement can be at least one blade, at least one particulate filler and/or at least one surface-increasing substrate being made of a single mould. A system can also be provided comprising at least two bags, whereas the bags may be interconnected via at least one aperture in their bag wall, and a cultivation process using such a bag or system, in which at least one type of cells, tissue, tissue-like cell cultures, organs, organ-like cell cultures, or multicellular organisms are cultivated in the presence of at least one fluid or solid medium provided for growing and/or cultivating the aforesaid culture.08-28-2008
20100136679Apparatus and Method for Processing Biological Material - The application discloses an apparatus and method for processing biological material, including a suspension of cells.06-03-2010
200901240019-AMINO-ACRIDINE DERIVATIVES AND THEIR USE FOR ELIMINATING MISFOLDED PROTEINS - The invention relates to compounds according to general formula (1) and/or their enantiomers, diastereomers as well as their pharmaceutically compatible salts, and to the use thereof for producing a medicament suited for treating diseases associated with misfolded proteins.05-14-2009
20120196358DEVICE FOR REMOVING CUMULUS FROM OOCYTES - Disclosed herein are devices, methods, and kit of parts adapted for stripping cumulus from a plurality of oocytes contained therein.08-02-2012
20100273255Human micrornas and methods for inhibiting same - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a microRNA shown in SEQ ID NOs: 1-94; 281-374; 467-481; 497-522; or 549, except that up to thirty percent of the bases may be wobble bases, and up to 10% of the contiguous bases may be non-complementary. The invention further relates to modified single stranded microRNA molecules, isolated single stranded anti-microRNA molecules and isolated microRNP molecules. In another embodiment, the invention relates to a method for inhibiting microRNP activity in a cell.10-28-2010
20090029455CHIMERIC T1R1 TASTE RECEPTOR ENCODING NUCLEIC ACID SEQUENCES AND VECTORS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.01-29-2009
20110207213Photoreactive Synthetic Regulator of Protein Function and Methods of Use Thereof - The present disclosure provides a photoreactive synthetic regulator of protein function. The present disclosure further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present disclosure further provides methods of modulating protein function, involving use of light.08-25-2011
20110207212T1R TASTE RECEPTORS AND GENES ENCODING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.08-25-2011
20110207211EXPRESSION OF IMMUNOGLOBULIN-CYTOKINE FUSION PROTEINS IN MALIGNANT B CELLS - According to the invention, there is provided a vector for the expression of immunoglobulin-cytokin fusion proteins in malignant B cells at least containing operably linked to each other08-25-2011
20090124002ALPHA-1D CALCIUM CHANNEL EXPRESSED IN ATRIUM - Novel calcium channel nucleic acids and polypeptides are disclosed herein. Methods of using the novel nucleic acids and polypeptides are also disclosed.05-14-2009
20090137034METHODS FOR PERFUSION AND PLATING OF PRIMARY HEPATOCYTES AND A MEDIUM THEREFORE - The present invention provides methods for culturing primary hepatocytes with improved long term function and improved viability, by plating the hepatocytes in the presence of an anti-oxidant(s) as well as an agent(s) which is a functional inhibitor of enzymes that generate reactive oxygen and reactive nitrogen species. One preferred embodiment provides a combination of 2-oxo-thizolidine and tocopherol succinate. Another preferred embodiment provides a combination of N05-28-2009
20110217769CELL-TYPE SPECIFIC APTAMER-siRNA DELIVERY SYSTEM FOR HIV-1 THERAPY - The present invention relates to compositions and methods for delivery of siRNA to specific cells or tissue. More particularly, the present invention relates to compositions and methods for cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer.09-08-2011
20090061510ANTI-ANGIOGENIC POLYPEPTIDES - Anti-angiogenic polypeptides A03-05-2009
20090137035TWEAK RECEPTOR - The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.05-28-2009
20090029456STR50 and uses thereof - The present invention relates to use of a novel gene, STR50 and to STR50 modulators in diagnostic, therapeutic and screening aspects related to neurotoxic events. More particularly, the present invention concerns diagnosing and treating neurodegenerative diseases, and screening for species which can be useful in treating the same.01-29-2009
20090325286METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.12-31-2009
20090325285METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.12-31-2009
20110143429TISSUE ENGINEERED BLOOD VESSELS - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed.06-16-2011
20100184210METHOD FOR ISOLATING CELLS07-22-2010
20110143428ANTI-VEGF-C ANTIBODIES AND METHODS USING SAME - The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression.06-16-2011
20110143427HIGH-THROUGHPUT METHODS AND SYSTEMS FOR PROCESSING BIOLOGICAL MATERIALS - A high-throughput system for processing biological material that comprises: a tray that supports a functionally-closed fluid path subsystem comprising, a vessel for containing and enabling the biological material to separate into two or more distinct submaterials; one or more receptacles to receive one or more of the submaterials from the vessel; a filtration device; a conduit through which one or more submaterials are transported between at least the vessel and the filtration device; and a first engagement structure; a processing unit comprising, a pumping device for moving one or more of the submaterials between at least the vessel and the filtration device via the conduit; a second engagement structure corresponding to the first engagement structure; a locking mechanism for at least temporarily holding the tray in a fixed position relative to the processing unit; a control device that automatically starts and stops the pumping device in response to one or more commands.06-16-2011
20090197329APPARATUS AND METHOD FOR SEPARATING BIOLOGICAL PARTICLES USING DIFFERENCE BETWEEN GRAVITY AND MAGNETIC FORCE - Disclosed is an apparatus and method for injecting liquid-drops of particle mixture liquid including a mixture of biological particles, affecting magnetic field, and having only positive particles, which are combined with magnetic responsive material, separated by magnetic force, and having negative particles, which are not combined with magnetic responsive material, precipitated by gravity.08-06-2009
20090191624Use of transthyretin peptide/protein fussions to increase the serum half-life of pharmacologically active peptides/proteins - The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.07-30-2009
20090053802Multipotent stem cells from peripheral tissues and uses thereof - This invention relates to multipotent stem cells, purified from the peripheral tissue of mammals, and capable of differentiating into neural and non-neural cell types. These stem cells provide an accessible source for autologous transplantation into CNS, PNS, and other damaged tissues.02-26-2009
20090017533OPTIMIZED MESSENGER RNA - The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.01-15-2009
20090004735Promoter and its use - A promoter comprising nucleotides from positions 2489-3038 of FIG. 01-01-2009
20090203129MULTIPOTENT ADULT STEM CELLS AND METHODS FOR ISOLATION - The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.08-13-2009
20090209034TUMOUR REJECTION ANTIGENS - Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.08-20-2009
20110143430HEMATOPOIETIC STEM CELL IDENTIFICATION AND ISOLATION - The present invention relates to methods of identifying, collecting and isolating hematopoietic stem cells (HSCs) and compositions of purified HSCs. Specifically, the present invention provides methods of isolating and purifying CD15006-16-2011
20090117650MODIFIED GREEN FLUORESCENT PROTEINS AND METHODS FOR USING SAME - The present invention provides nucleic acid molecules encoding mutant fluorescent proteins as well as proteins encoded by these nucleic acids. In addition, host-cells, stable cell lines and transgenic organisms comprising the above-referenced nucleic acid molecules are provided. The subject protein and nucleic acid compositions find use in a variety of different applications and methods, particularly for labeling of biomolecules, cells, or cell organelles.05-07-2009
20090253200CADHERIN-11 ANTAGONISTS AND METHODS FOR THE TREATMENT OF INFLAMMATORY JOINT DISORDERS - The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumatoid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist.10-08-2009
20090246867Glial mitogenic factors, their preparation and use - Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.10-01-2009
20090253201Embryonic stem cells capable of differentiating into desired cell lines - An embryonic stem cell which may be induced to differentiate homogeneously into a desired primary cell line. The embryonic stem cell may be engineered with DNA, which encodes a protein or polypeptide which promotes differentiation of the stem cell into a specific cell line, such as, for example, a neuronal cell line, a muscle cell line, or a hematopoietic cell line. The DNA may encode a transcription factor found in the particular cell line. In another alternative, a desired cell line is produced from embryonic stem cells by culturing embryonic stem cells under conditions which provide for a three-dimensional network of embryonic stem cells, and then stimulating embryonic stem cells with an agent, such as retinoic acid, or dimethylsulfoxide, which promotes differentiation of the embryonic stem cells into the desired cell line, such as, for example, a neuronal cell line, or a muscle cell line.10-08-2009
20090258417Culture Vessel and a Method of Culture - A culture vessel comprising a gas permeable film which has oxygen permeability of P10-15-2009
20100248359Anti-Glypican 3 Antibody - An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.09-30-2010
20100248358CELL SEPARATING APPARATUS AND CELL SEPARATING METHOD - A cancer cell separating apparatus includes: a flow channel including an antibody fixation area having antibodies which bind specifically to cancer cells fixed thereon, wherein the cancer cells and non-cancer cells are separated using a difference in velocity of movement between the cancer cells and the non-cancer cells in cell slurry introduced into the flow channel.09-30-2010
20090258418Reactive 1,3'-crosslinked carbocyanines and their bioconjugates - Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3′-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.10-15-2009
20100248357Nematode Fatty Acid Desaturase-Like Sequences - Nucleic acid molecules from nematodes encoding fatty acid desaturase polypeptides are described. Fatty acid desaturase-like polypeptide sequences are also provided, as are vectors, host cells, and recombinant methods for production of fatty acid desaturase-like nucleotides and polypeptides. Also described are screening methods for identifying inhibitors and/or activators of fatty acid desaturase-like polypeptides, as well as methods for antibody production.09-30-2010
20100015701NOVEL FLUORESCENT PROTEINS AND METHODS FOR USING SAME - The present invention provides nucleic acid molecules encoding novel red fluorescent proteins from 01-21-2010
20100159585Suppressor tRNA Transcription in Vertebrate Cells - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNA's/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in vertebrate cells are also provided.06-24-2010
20130122584SYSTEMS AND METHODS FOR THE DIGESTION OF ADIPOSE TISSUE SAMPLES OBTAINED FROM A CLIENT FOR CRYOPRESERVATION - The present invention is directed to systems and methods of processing aspirated adipose tissue for the isolation of stromal vascular fraction derived stem cells.05-16-2013
20100261269Activation and Expansion of T-Cells Using An Engineered Multivalent Signaling Platform as a Research Tool - Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.10-14-2010
20110177589NOVEL HUMAN POLYOMAVIRUS - Provided herein is a novel human polyomavirus, its nucleic acid sequence, as well as methods to detect and diagnosis the presence of the polyomavirus.07-21-2011
20100184211Tumour-Associated Peptides that Bind to MHC Molecules - The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.07-22-2010
20110111493Compositions and Methods For Inhibiting Expression Of A Target Gene - The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3′-end and a blunt 5′-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.05-12-2011
20090017534SLO2 AND SLO4, NOVEL POTASSIUM CHANNEL PROTEINS FROM HUMAN BRAIN - The invention provides isolated nucleic acid and amino acid sequences of Slo2 and Slo4, members of the Slo family of potassium channel proteins, also known as “maxi” or BK potassium channel proteins. Also provided herein are antibodies to Slo2 and Slo 4, methods of detecting Slo2 and Slo 4, methods of screening for potassium channel activators and inhibitors using biologically active Slo2 and Slo 4, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising Slo2 and Slo 4.01-15-2009
20100197007Method for Culturing Mammalian Stem Cells - The invention relates to a method for culturing mammalian stem cells, in particular embryonic stem cells comprising the following steps: a) providing a perfused bioreactor (08-05-2010
20100227392Use of RPA32, RPA4, and RPA4/RPA32 Hybrid Polypeptides and Polynucleotides for Assessing and Modulating Cell Proliferation - Disclosed are polynucleotides and polypeptides that are useful for assessing and modulating cell proliferation. The polynucleotides may comprise coding regions for RPA4 and RPA4/RPA32 hybrid polypeptides. The polynucleotides may be used in gene vectors for modulating cell proliferation in a patient in need thereof. Diagnostic methods related to assaying RPA4 expression in test samples in order to detect proliferating or cancerous cells also are disclosed.09-09-2010
20100227393LIVER STEM CELLS: ISOLATION OF HEPATIC PROGENITOR CELLS FROM THE HUMAN GALL BLADDER - Methods of preparing multipotent cell populations from gallbladder are provided. Also provided are enriched multipotent cell populations from gallbladder and methods of differentiating the multipotent cell populations to prepare, for example, hepatocytes.09-09-2010
20080213880CHIMERIC T1R1 TASTE RECEPTOR ENCODING NUCLEIC ACID SEQUENCES AND VECTORS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.09-04-2008
20100240125BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE - A bone delivery conjugate having a structure selected from the group consisting of: A) X-D09-23-2010
20110059523Heat Transfer Baffle System and Uses Thereof - This disclosure describes an improved heat transfer system for use in reaction vessels used in chemical and biological processes. In one embodiment, a heat transfer baffle comprising two sub-assemblies adjoined to one another is provided.03-10-2011
20100227394FUSION ANTIBODIES - The present invention provides novel antibodies. In particular, the present invention provides fusion antibodies comprising antibody heavy and light chain fusions. The present invention further provides multivalent antibodies comprising multiple fusion antibody chains. The present invention further provides methods of generating splice resistant antibody genes.09-09-2010
20120129252METHOD AND SYSTEM FOR CELL FILTRATION - Methods and systems disclosed in the present application include membrane-like filters and methods and systems that employ these membrane-like filters to isolate circulating tumor cells and other abnormal cells from biological fluids, such as blood. The disclosed methods and systems use membrane-like filters that include a pattern or array of small, tapered apertures fabricated within a relatively thin but mechanically robust polymeric material that resists accumulation of biological-solution components and clogging during filtration of biological solutions.05-24-2012
20120129253ADIPOSE TISSUE-DERIVED STROMAL CELLS AND METHODS OF ISOLATING AND USING THE SAME - Adipose tissue-derived stromal cells and methods of isolating and using the same. In at least one embodiment of isolated adipose tissue-derived stromal cells of the present disclosure, the cells are isolated by performing adipose tissue resection or suction on a mammalian patient, dissecting tissue obtained from said tissue resection or suction and dissociating said tissue into a cell suspension, removing adipocytes from the cell suspension, culturing the adipocyte-depleted cell suspension in EGM-2-MV media, and isolating adipose tissue-derived stromal cells secreting vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and granulocyte-colony stimulating factor (G-CSF).05-24-2012
20100255571METHOD AND DEVICE FOR FIXING/STABILISING A SAMPLE - The present invention provides a method for fixing and/or stabilizing a sample, in which the sample is put into a permeable container, the permeable container having an opening, which is pressed into the sample, then a portion of the sample brought into the permeable container in this way is separated from the rest of the sample, and the container filled with the sample in this way is immersed in fixing and/or stabilizing agents and the sample is fixed and/or stabilized.10-07-2010
20100255572INFLAMMATION-INDUCED ANTI-FLAMMATORY GENE EXPRESSION - According to one embodiment of the present invention, a self regulating DNA non-viral expression vector is provided that allows after non-viral ex vivo gene therapy for the controlled and regulable inflammation-specific expression of anti-inflammatory polypeptide gene products in the recipient's joint tissues. The inventive gene expression construct comprises a RNA polymerase promoter sequence that is induced by inflammation and which is operable in a mammalian cell, a transcribed sequence under the control of said promoter sequence, encoding a transcription product that has the ability to modulate the inflammatory response, and/or encoding the mRNA for a polypeptide gene product that has the ability to modulate the inflammatory response, whereby the inflammatory response is modulated by a negative feed back response of said gene product on said promoter sequence.10-07-2010
20100136680BAGLIKE CONTAINER FOR CENTRIFUGATION AND METHOD OF GENE TRANSFER USING THE SAME - Baglike container (06-03-2010
20120142088DNA-CELL CONJUGATES - The present invention provides conjugates of DNA and cells by linking the DNA to a native functional group on the cell surface. The cells can be without cell walls or can have cell walls. The modified cells can be linked to a substrate surface and used in assay or bioreactors.06-07-2012
20100203628Novel modified galectin 9 proteins and use thereof - It is suggested that recombinant galectin 9 (rGal 9), produced in host 08-12-2010
20100197006MOLECULAR CIRCUITS - Disclosed herein are autonomous molecular circuits that can function in cells. The circuits can process logical operations in which one or more input cues are among the operands and produce an appropriate output. Such circuits can be implemented in living cells, e.g., eukaryotic or prokaryotic cells that have been modified to include circuit components. The molecular circuits and cells containing the circuits can be used in a variety of applications including, e.g., diagnostics, therapeutics, and protein production.08-05-2010
20100197005HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1 - The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.08-05-2010
20090239295Dedifferentiated, Programmable Stem Cells of Monocytic Origin, and Their Production and Use - The invention relates to the production of adult dedifferentiated, programmable stem cells from human monocytes by cultivation of monocytes in a culture medium which contains M-CSF and IL-3. The invention further relates to pharmaceutical preparations, which contain the dedifferentiated, programmable stem cells and the use of these stem cells for the production of target cells and target tissue.09-24-2009
20090203125MIG-7 AS A SPECIFIC ANTICANCER TARGET - Aspects of the present invention provide novel Mig-7 encoding nucleic acids and Mig-7 polypeptides, recombinant DNA expression systems and host cells containing same, as well as methods of inhibiting expression of the subject nucleic acid molecules, inhibiting production of the encoded proteins or polypeptides, inhibiting metastasis of a carcinoma cell in a subject (including in humans), inhibiting migration/invasion of and mimicking of normal cells by carcinoma cells in a subject, detecting the presence of a cancer cell (e.g., a migrating/invading cancer cell or carcinoma cell mimic, and tumor neovascularization) in a sample of a subject's tissue or body fluids, and inhibiting the migration/invasion of or endothelial cell mimicking by a placental cell into the blood stream or vessels of a female mammal. Particular aspects relate to novel anti-Mig-7 antibodies, diagnostic and/or prognostic methods, and therapeutic methods comprising use of the inventive nucleic acids, polypeptides and antibodies or derivatives thereof.08-13-2009
20110111494MULTIMERIC TNF RECEPTORS - The present invention refers to fusion proteins comprising a TNF receptor family extracellular domain fused to a trimerization domain, and a nucleic acid molecule encoding the fusion protein. The fusion protein may be present as a trimeric complex. It is suitable for therapeutic, diagnostic and/or research applications.05-12-2011
20110117644DR5 gene promoter and SIAH-1 gene promoter - The inventors discovered for the first time the nucleotide sequence of the human DR5 gene promoter, the nucleotide sequence of the human Siah-1 gene promoter and what appear to be the core promoter regions thereof. The present invention further provides a screening method for substances which regulate promoter activity, comprising a step of bringing a test substance into contact with cells holding a vector which comprises this DNA together with a reporter gene ligated expressibly to this DNA, and a step of detecting changes in the expressed amount of the reporter gene due to contact with the test substance. This screening method is a method of very efficiently selecting anti-cancer drugs and the like.05-19-2011
20100297754DEVICE FOR CARRYING OUT CELL LYSIS AND NUCLEIC ACID EXTRACTION - The present invention provides an integrated lab-on-a-chip device for carrying out a nucleic acid extraction process on a fluid sample containing cells and/or particles, the device comprising: (a) a sample inlet (11-25-2010
20100311159METHODS FOR PURIFYING OR DEPLETING MOLECULES OR CELLS OF INTEREST - A method of separating a target molecule or cell of interest from a sample is provided. The method comprising:12-09-2010
20090075371Regenerative Medicine Devices and Foam Methods of Manufacture - The invention relates generally to devices for organ replacement and regenerative medicine providing a biocompatible and biodegradable scaffold capable of integral cell growth that forms a hollow chamber, as well as methods for producing such devices by lyophilizing biocompatible, biodegradable polymers to produce a seamless, three-dimensional shape.03-19-2009
20130164838METHOD FOR ENRICHMENT OF DNA STRAND BREAK-FREE SPERMATOZOA AND REDUCTION OF RISKS FOR ABNORMALITIES AND/OR ANEUPLOIDY - Method for producing an enriched DNA strand break-free spermatozoa sample of a poor quality seminal fluid, wherein in the method a selecting device which comprises two chambers and a bridge element is used and the method comprises the following steps placing a seminal fluid which comprises at least 15% oligo-, at least 32% astheno-, and/or at least 4% teratozoospermia, based on the total amount of the spermatozoa in the seminal fluid, in the first chamber of the selecting device, filling the second chamber of the selecting device with a medium for receiving DNA strand break-free spermatozoa and connecting both chambers by the bridge element such that a fluid bridge between the first and second chamber occurs which allows the DNA strand break-free spermatozoa to move from the first to the second chamber. The obtained DNA strand break-free spermatozoa sample shows a high quality and can be used in various applications. Furthermore, the present invention relates to means and methods for the reduction of the risk of congenital abnormality or aneuploidy in an artificial reproductive technology comprising the selection and/or enrichment of spermatozoa and for the selection and/or enrichment of spermatozoa that have a reduced risk of inducing or leading to a congenital abnormality or aneuploidy after in vitro fertilization.06-27-2013
20110033923MARKER FOR STEM CELLS AND ITS USE - A marker for mesenchymal stem cells (MSC) is provided, comprising an integrin alpha10 chain and/or an integrin alpha11 chain expressed on the cell surface of or intracellular in a MSC. The marker is used in methods for identification of mammalian MSC and in methods for isolation of MSC. Also included are isolated cellular populations of mammalian MSC and a cellular composition comprising the latter. Moreover, uses of said marker for isolation, modulation and identification of mammalian MSC are provided.02-10-2011
20110039329Growth factor extractor - A reservoir is supported by a base in a vertical position. A reciprocating member is positioned in the reservoir forming an internal chamber. The chamber receives growth factor starting material through an inlet in the reciprocating member. After the inlet is sealed, the reciprocating member increases the volume of the chamber to apply negative pressure to the growth factor starting material within to produce activated growth factors. The activated growth factors are extracted from the chamber through an outlet in the reciprocating member. Optionally, the growth factor starting material is held in the chamber to separate into fractions.02-17-2011
20110033926Production Of Viral Vectors - The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.02-10-2011
20110033924Apparatus and Method for Filtering Biological Material - A method and apparatus for harvesting cells from a fluid so as to preserve the integrity of the cells when used in the diagnosis of cancer. The apparatus comprises a filter adapted to collect cells of a predetermined size, a fluid pathway arranged to transmit fluid to and from the filter, a pump which provide a positive pressure which urges the fluid to the filter along the fluid pathway and a negative pressure which draws the fluid from the filter along the fluid pathway and which operates to pass the sample through the filter in a first direction to collect cells on the filter. A second pump operates to pass a cell preservative fluid through the filter in a second direction to remove cells from the filter for collection. A controller is provided to regulate the flow of fluid along the fluid pathway. The method and apparatus provides a gentle pressure gradient which minimises damage to the cells during the process of filtration and collection.02-10-2011
20100178697SYSTEM, APPARATUS AND METHOD FOR MATERIAL PREPARATION AND/OR HANDLING - Oscillating angularly rotating a container containing a material may cause the material to be separate. Denser or heavier material may unexpectedly tend to collected relatively close to the axis of rotation, while less dense or light material may tend to collect relatively away from the axis of rotation. Oscillation along an arcuate path provides high lysing efficiency. Alternatively, a micromotor may drive an impeller removably received in a container. Lysing may be implemented in batch mode, flow-through stop or semi-batch mode, or flow-through continuous mode. Lysing particulate material may exceed material to be lysed or lysed material and/or air may be essentially eliminated from a chamber to increase lysing efficiency.07-15-2010
20110033922MICROCHIP-BASED ACOUSTIC TRAPPING OR CAPTURE OF CELLS FOR FORENSIC ANALYSIS AND RELATED METHOD THEREOF - The present invention provides a method and apparatus for separating by size a mixture of different size particles using ultrasound. The apparatus contains a microchannel having an acoustic transducer thereon. As a mixture of cells having different sizes flows down the microchannel, the ultrasonic radiation traps cells of desired sizes focused at nodes of a standing pressure wave in the microchannel.02-10-2011
20110111492Stem Cell Aggregates and Methods for Making and Using - The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stern cells but can differentiate into cell types of at least two of ectodermal, undo dermal, and mesodermal embryonic germ layers, e.g., stem cells.05-12-2011
20110111491RNA INTERFERENCE SUPPRESION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF - The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules.05-12-2011
20110244561siRNA-MEDIATED GENE SILENCING - The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules.10-06-2011
20110244563ASSAYS THAT USE THE T1R1 RECEPTOR POLYPEPTIDES TO SCREEN FOR T1R1-ASSOCIATED TASTE MODULATORS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.10-06-2011
20110244562RNA INTERFERENCE SUPPRESSION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF - The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence that encodes poly-glutamine repeat diseases, and methods of using these RNAi molecules.10-06-2011
20100136682Polyvalent RNA-Nanoparticle Compositions - The present invention concerns nanoparticles functionalized with duplex RNA for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a new strategy for conjugating RNA to a nanoparticle to achieve increased stability and activity.06-03-2010
20110129915APPARATUS AND METHOD FOR INCUBATING CELL CULTURES - A portable, self-contained incubation apparatus has a cell container in which a cell culture can grow. The cell container resides on a base along with other components that maintain the environmental conditions inside of the container within a desired range. The self-contained incubation apparatus is portable allowing the conditions within the cell container to be precisely controlled even as it is being moved from one location to another. Further, at least one transparent surface of the cell container enables observation of the cell culture. Thus, the culture can be observed while the environmental conditions within the container are being controlled by components of the incubation apparatus. Since the cells can be observed without breaking the air-tight seal of the container, observation of the cells can be performed as often as is desired without introducing contaminants to the culture or otherwise significantly affecting the growth environment within the container. Indeed, observation of the cells can be performed as often as is desired without introducing contaminants to the culture or otherwise significantly affecting the growth environment within the container.06-02-2011
20090311780MINIMALLY IMMUNOGENIC VARIANTS OF SDR-GRAFTED HUMANIZED ANTIBODY CC49 AND THEIR USE - Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28′ CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72.12-17-2009
20110212522MICRO-CHAMBER PROCESSING APPARATUS FOR CELL CULTURE AND METHOD - This invention relates to a method and apparatus for process cell cultures. The apparatus comprises a micro-chamber comprising no more than one absorption layer and at least one gel layer, in this order, laminated on a transparent base plate having no conspicuous absorbency in visible and infrared regions, and at least one light source, said absorption layer having absorbency in visible and infrared regions, and said gel-like material being a substance which has a gel dissolution temperature of 100 degree C. or less, solates when heated and is in a gel state at room temperature and has absorbency for a specific wave length of visible and infrared regions, and said light source having a monochromatic light in said specific wave length, wherein said light source is disposed such that it irradiates on said absorption layer and/or said gel layer, with the exception that when no absorption layer is provided, at least two layers each composed of a gel-like material are laminated on said transparent base plate.09-01-2011
20110212521Apparatus and Method for Generating a Tool Motion - The invention relates to an apparatus according to the present invention for generating the motion of a tool, in particular for the work on biological cell material, in particular for performing ICSI, comprises at least one actuator element, an actuated member, a motion section, at which can be arranged a tool and which is linked to the actuated member, the actuated member being elastically deformable, the actuator element being linked to the actuated member such that an actuation by the actuator element elastically deforms the actuated member by a distance, which corresponds to a length change of the actuated member, wherein said length change causes said motion of the motion section. Further, a corresponding method for generating a tool motion is provided.09-01-2011
20110212520RNA INTERFERENCE SUPPRESSION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF - The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules.09-01-2011
20110212518EXPRESSION VECTOR AND METHODS OF PRODUCING HIGH LEVELS OF PROTEINS - A process for high expression of protein of interest using an expression vector. The process comprises at least the following regulatory elements: a) a CMV promoter, or its functional variants, b) an intron, c) TPL or its functional variants, d) VA genes or functional variants, and e) a bovine growth hormone polyadenylation sequence or functional variants.09-01-2011
20110086422HUMANIZED ANTIBODIES TO INTERFERON ALPHA RECEPTOR-1 (IFNAR-1) - Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.04-14-2011
20090311779ANTI-P-SELECTIN ANTIBODIES - This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).12-17-2009
20100009438DENDRITIC CELL POTENTIATION - A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are compositions containing the molecule and methods for using the compositions to treat or immunize individuals.01-14-2010
20100009436High throughput assays for transmissible spongiform encephalopathies (TSE) - Stable cell lines which produce the pathological form of PrP after infection with the infectious agent for CJD provide a high throughput assay to identify suitable treatment protocols and compositions. The stable cell lines also provide rich source of infectious CJD agent. They also may be used to identify vaccine candidates. Co-culture of neuronal cells with cells to be tested for infection with a TSE agent also provides a high throughput method for identifying infected cells.01-14-2010
20090035850P49/STRAP is a novel protein involved in gene regulation and cell proliferation - The invention provides isolated p49/STRAP protein, and isolated nucleic acids encoding a p49/STRAP protein. The inventors have discovered a new protein, named p49/STRAP that is expressed in cardiac tissue and other tissues in mammals. The p49/STRAP protein binds to serum response factor (SRF) and regulates transcription of SRF-responsive genes in the heart. p49/STRAP is also discovered to inhibit tumor cell proliferation, and thus the invention provides a method of inhibiting cancer cell proliferation by contacting the cells with p49/STRAP.02-05-2009
20100055779CELL CULTURE VESSEL, PRODUCTION PROCESS THEREOF AND CULTURED CELL - An object of the present invention is to provide a cell culture vessel which is simple in structure and easy to handle, and is capable of preventing damage to the cells when separated, promoting transport of nutrients and excretion of effete matter, and elevating the culturing efficiency improving effect by the structural features. In order to attain the above object, there is provided a cell culture vessel including a culture section provided with a plurality of projections having an equivalent diameter smaller than the cells to be cultured and the culture section side walls enclosing the culture section, wherein the distance between an arbitrary position on the culture section/side wall boundary line and the nearest projection is smaller than the diameter of the cells to be cultured. The effect of the projections in the vessel given to the cultured cells is enhanced.03-04-2010
20100055778MAMMALIAN ZCYTOR 11 - Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in pancreas, small intestine, colon and thymus. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of these organs.03-04-2010
20090215169Method for regulating protein function in cells using synthetic small molecules - Methods and compositions for the rapid and reversible destabilizing of specific proteins using cell-permeable, synthetic molecules are described. Stability-affecting proteins, e.g., derived from FKBP and DHFR proteins are fused to a protein of interest and the presence or absence of the ligand is used to modulate the stability of the fusion protein.08-27-2009
20090215170Plexin family-like polypeptide, DNA encoding the same and uses thereof - The present invention is directed to a novel plexin family like DNA, a gene containing the DNA, novel polypeptide encoded by the DNA, a recombinant protein containing the polypeptide or heterologous polypeptide sequences, antibodies which bind to the polypeptides, methods for producing the polypeptides of the present invention. Conditions that can be diagnosed, screened, prevented, or treated by the compositions herein include prophylactic, angiogenesis and conservation of functions in various organs, angiogenesis at the time of tumor and regeneration of various organs, proliferation, differentiation and preservation of function of the cells in various organs, aging, and dysfunction of the present invention.08-27-2009
20110097793CELL SEPARATION DEVICE, CELL SEPARATION SYSTEM AND CELL SEPARATION METHOD - A cell separation device which can perform a continuous processing without bonding fluorescent molecules or magnetic particles to the surface of the cell membrane, a cell separation system, and a cell separation method, wherein when a sample cell suspension containing the desired target cells is supplied continuously from a sample inlet and physiological saline is supplied continuously from a physiological saline inlet, the sample cell suspension flows together with the physiological saline in a liquid flow path and an adsorption force acts on the target cells due to affinity bonding from the adsorbing portions of adsorbing regions in the form of strips formed in a planar wall portion. Since the adsorbing regions in the form of strips are disposed in an asymmetric fashion to the flow path direction of the liquid flow path, the adsorption force acting on the target cells has a constituent perpendicular to the flow path direction. As a result, the target cells shown in 04-28-2011
20110097792INTERLEUKIN-12P40 VARIANTS WITH IMPROVED STABILITY - Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.04-28-2011
20110076762ARTICLES FORMED BY MANUFACTURING PROCESSES, SUCH AS THREE-DIMENSIONAL PRINTING, INCLUDING SOLVENT VAPOR FILMING AND THE LIKE - Methods of manufacturing an article use three-dimensional printing for a portion of the manufacturing. Three-dimensionally printing is conducted onto a powder bed which contains both organic-solvent-soluble, water-insoluble particles and water soluble, organic-solvent-insoluble particles. The water-soluble particles which may be selected for properties such as size and may include more than one substance. The organic-solvent-insoluble particles may further include at least one substantially insoluble substance such as a member of the calcium phosphate family. Printing may be done using an aqueous binder liquid. After removal of unbound powder, the preform may be exposed to the vapor of an organic solvent which causes the particles of organic-soluble-polymer to fuse to each other. This may further be followed by dissolving out the water-soluble particles, if such particles were present in the powder. Solvent vapor fusing together with the use of porogen particles may also be used in manufacturing methods other than 3DP. Rather than using organic solvent, heat responsive particles can be used, and can be filmed by elevated temperatures. Articles that may be produced by the described methods exhibit features such as a high porosity and an ability to undergo large deformations without breaking, and by at least partial springback from such deformation. The springback may be substantially instantaneous or may be time-dependent involving a time period of at least several seconds.03-31-2011
20090104692Tissue Container for Molecular and Histology Diagnostics Incorporating a Breakable Membrane - A container for storing a biological sample for molecular diagnostic testing and/or histological testing is provided. The container includes a first chamber for receiving a sample holder therein, a second chamber, and a closure for enclosing the container. A breakable membrane, such as a piercable foil, extends within the container and separates the two chambers. When the breakable membrane is broken, fluid can pass between the first and second chambers. The membrane may be broken through an activator on the closure, such as a depressible member or a rotatable carrier, causing the sample holder to break through the membrane.04-23-2009
20110059522NUCLEIC ACIDS ENCODING A HOUSE DUST MITE ALLERGEN, DER P III, AND USES THEREOF - Isolated nucleic acids encoding an allergen of 03-10-2011
20120202284CELL SORTING APPARATUS AND METHOD - Apparatus and method for sorting cells is provided in which two or more cells are delivered along a flow path, the two or more cells including a first type of cells having a first mechanical stiffness and at least a second type of cells having a second mechanical stiffness different from the first mechanical stiffness. A reflection surface is provided across the flow path at an oblique angle relative to the flow path and configured to reflect the cells at different reflection angles relative to the flow path dependent on the mechanical stiffness of the cells.08-09-2012
20110008884PATHOLOGY GROSSING TOOL, CASSETTE, AND BOARD - A pathology grossing tool and board are provided for the preparation from a gross tissue of a uniformly thin tissue specimen, which is suitable for processing for histology, histochemistry, antibody binding, genetic analysis, or the like. A tissue cassette for receiving the tissue sample, providing a flat-cutting surface along its upper edge, and holding the thin tissue specimen is also provided. Methods for their use are provided.01-13-2011
20100297753TRANSFECTION BY LASER PORATION ON ROTATING CYLINDER - Biological cells are transfected by a laser poration process in which the structures are immobilized on a solid surface that is cylindrical in shape, and the cylinder, while immersed in a liquid solution of the transfecting species or otherwise in contact with the solution, is rotated past a stationary laser such that the laser beam spans the entire circumference of the cylinder and all cells immobilized thereon. Axial movement of the cylinder or the laser in addition to the rotational movement brings the entire length of the cylinder within the influence of the laser as well as the cylinder circumference.11-25-2010
20090023206MICROINJECTION APPARATUS AND METHOD OF INJECTING FLUID - A microinjection apparatus allows a capillary to stick into an object. A discharge pressure is supplied to the capillary. The supplied discharge pressure allows the discharge of a first fluid from the tip end of the capillary. The first fluid is injected into the object. The remains of the object possibly adhere to the tip end of the capillary. A pipe member defines a flow passage for a second fluid directed toward the tip end of the capillary. The second fluid thus flows toward the tip end of the capillary. The second fluid allows the removal of the remains from the tip end of the capillary. The mentioned action of removing the remains does not interrupt the injection of the first fluid into the object. The injection of the first fluid is continuously applied to the objects with efficiency.01-22-2009
20100255573EXTRACTION AND PURIFICATION OF BIOLOGIGAL CELLS USING ULTRASOUND - A process is described in which biological cells are separated from a material sample, such as blood or soil, in which the material sample is formed as a suspension in a fluid and introduced into a chamber. One or more acoustic pressure nodes aggregate the material sample, and a flow of fluid removes soluble matter from the aggregate leaving the biological cells and other inert materials at the node(s). In one aspect of the invention the biological materials are separated from inhibitors that might render their subsequent analysis in, for example, a PCR system difficult. In another aspect of the invention a method is described to extract a clean DNA sample for such biological cells.10-07-2010
20110250680AUTOMATED SYSTEM FOR THE LYSIS OF MICROORGANISMS PRESENT IN A SAMPLE, FOR EXTRACTION AND FOR PURIFICATION OF THE NUCLEIC ACIDS OF SAID MICROORGANISMS FOR PURPOSES OF ANALYSIS - The present invention relates to, among other things, a device for collecting airborne microorganisms, said device having: 10-13-2011
20100003748COMPOSITIONS, SYSTEMS, AND METHODS FOR STABILIZATION OF A CELL AND/OR MACROMOLECULE - The present disclosure relates to compositions, systems, and methods for stabilizing a cell (e.g. a whole cell), a biomolecule, and/or a macromolecule. A biomaterial stabilizing composition may include a chelator, a chelator enhancing component, a base (e.g., a purine base or a pyrimidine base), and optionally a protease inhibitor and/or a kosmotrope. A biomaterial stabilizing method may include contacting a cell with a biomaterial stabilizing composition. A cell stabilizing system may include a container suitable for receiving a sample containing a cell and a biomaterial stabilizing composition. A cell may be stabilized under ambient conditions (e.g., without refrigeration). A cell may include a protein, a nucleic acid, and/or another biomolecule marker of cell stabilization. A composition may be configured to stabilize one or more cells for analysis by flow cytometry and simultaneously stabilize one or more intracellular nucleic acids for molecular analysis.01-07-2010
20100003747CULTURED XENOPUS LAEVIS CELL LINES EXPRESSING MUTANT ADENOMATOUS POLYPOSIS COLI GENE - Using protein visualization techniques, cell lines stably expressing GFP-fused full-length and mutant APCs were obtained from cultured 01-07-2010
20110177592MAGNETIC APPARATUS FOR BLOOD SEPARATION - An apparatus for magnetically separating constituents of blood includes: a first portion having a solid support haying fixedly attached thereon a plurality of ring magnets, each ring magnet defining an interior perimeter enclosing an aperture; and a second portion removably attached to the first portion, wherein the second portion includes a solid substrate having surfaces defining a plurality of second apertures, each second aperture configured to removably hold a vial.07-21-2011
20110177591METHOD AND DEVICE FOR PRODUCING DERMIS - A process and a device for preparing a dermis implant of a predefinable thickness provides for a section of skin (07-21-2011
20090029457PHARMACEUTICAL COMPOSITION FOR INDUCING AN IMMUNE RESPONSE IN A HUMAN OR ANIMAL - The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.01-29-2009
20110256621COLLOIDAL MAGNETIC NANOBIOPARTICLES FOR CYTOTOXICITY AND DRUG DELIVERY - The present invention provides systems that include magnetic colloidal particles of differing elemental compositions with differing morphologies. The colloidal particles comprise a magnetic material and a shell that surrounds the magnetic material. The colloidal particles can be inductively heated using a magnetic field. The present invention also provides applications of such colloidal particles, such as methods for cytotoxicity and for drug delivery.10-20-2011
20110256620NUCLEIC ACID ENCODING A SELF-ASSEMBLING SPLIT-FLUORESCENT PROTEIN SYSTEM - The invention provides a protein labeling and detection system based on self-complementing fragments of fluorescent and chromophoric proteins. The system of the invention is exemplified with various combinations of self-complementing fragments derived from 10-20-2011
20080268532Dipeptidyl peptidases - Peptides including HisGlyTrpSerTyrGlyGlyPheLeu; LeuAspGluAsnValHisPhePhe; GluArgHisSerIleArg and PheValIleGlnGluGluPhe which show peptidase ability and have substrate specificity for at least one of the compounds H-Ala-Pro-pNA, H-Gly-Pro-pNA and H-Arg-Pro-pNA are disclosed. Nucleic acids, vectors, antibodies and hybridoma cells are also claimed with reference to the above sequences and their abilities.10-30-2008
20080213883SILICA NANOPARTICLES IN BASIC AMINO ACID-SILICA SOLS - In general, in one aspect, the invention features a method that includes preparing a mixture comprising water, a basic amino acid, and a metal oxide precursor under conditions which result in the formation of metal oxide nanoparticles from the metal oxide precursor.09-04-2008
20080213881Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof - The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.09-04-2008
20080213879Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level - A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer(CRET).09-04-2008
20080213882Method for Isolating Dermal Papilla Cells and Uses Thereof - The present invention relates to dermal papilla-specific markers and a method for isolating dermal papilla cells using the same. Dermal papilla cells isolated in accordance with the method of the invention and treated with BMP6 are useful for promoting hair growth.09-04-2008
20100304477POPULATION OF ADULT STEM CELLS DERIVED FROM CARDIAC ADIPOSE TISSUE AND USE THEREOF IN CARDIAC REGENERATION - The present invention relates to the isolation and characterization of a novel population of adult stem cells derived from fatty heart tissue, which constitutively express GATA-4 and/or Cx43. Said cell population can be used in cell therapy protocols in order to regenerate damaged myocardial tissue.12-02-2010
20100015702Generation, Characterization and Isolation of Neuroepithelial Stem Cells and Lineage Restricted Intermediate Precursor - Multipotent neuroepithelial stem cells and lineage-restricted oligodendrocyte-astrocyte precursor cells are described. The neuroepithelial stem cells are capable of self-renewal and of differentiation into neurons, astrocytes, and oligodendrocytes. The oligodendrocyte-astrocyte precursor cells are derived from neuroepithelial stem cells, are capable of self-renewal, and can differentiate into oligodendrocytes and astrocytes, but not neurons. Methods of generating, isolating, and culturing such neuroepithelial stem cells and oligodendrocyte-astrocyte precursor cells are also disclosed.01-21-2010
20110020927Method Of Transfecting Cells With Nucleic Acids Using Acidified Polyethylenimine - An object of the present invention is to achieve a method capable of increasing transfection efficiency of polyethyleneimine (PEI) and reducing toxicity thereof, to provide a PEI with high transfection efficiency, and to provide a method of introducing nucleic acids into cells comprising using the PEI.01-27-2011
20110053264FRAMEWORK RESIDUE SUBSTITUTED HUMANIZED COL-1 ANTIBODIES AND THEIR USE - The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.03-03-2011
20110053263Multipotent Cancer Stem Cell Lines and Method for Producing the Same - Provided is a multipotent cancer stem cell line derived from breast-cancer tissue and expressing a breast cancer stem cell marker. Also provided is a method for producing a multipotent cancer stem cell line, including (1) isolation of breast-cancer cells from previously extracted breast cancer tissue, (2) primary culture of the isolated breast cancer cells in a suspended state in a medium for suspension culture, (3) recovery of the cells in the suspended state from the primary culture, and (4) production of a multipotent cancer stem cell line by subculturing the recovered cells a predetermined number of times or more in a suspended state in the medium for suspension culture.03-03-2011
20110053262METHODS OF FABRICATING ENHANCED TISSUE-ENGINEERED CARTILAGE - Compositions and methods for fabricating a tissue-engineered cartilage construct comprising: providing a cell sample comprising a plurality of chondrocytes; culturing the cell sample to produce a tissue-engineered cartilage construct; and treating the tissue-engineered cartilage construct, wherein treating the tissue-engineered cartilage construct comprises the use of a biochemical reagent, a mechanical force, hydrostatic pressure, or any combination thereof.03-03-2011
20110053261METHODS FOR DETERMINING CORRELATED RESIDUES IN A PROTEIN OR OTHER BIOPOLYMER USING MOLECULAR DYNAMICS - The invention provides methods and systems of determining biopolymer profiles and correlations between structural units (residues) of a biopolymer based on sampling of the conformational space available to the molecule. The correlations between these structural units can further be used to find networks within a biopolymer such as the coupled residue networks in a protein. The invention also provides for designing and engineering biopolymers including polypeptides, nucleic acids and carbohydrates using the information derived from the conformation clustering and subsequent methods described herein.03-03-2011
20110027877RECIPIENT DEVICE AND METHOD TO PROTECT IN VITRO CULTURED EMBRYOS AND CELLS AGAINST ATOMOSPHERIC SHOCK - A recipient device comprises a base (02-03-2011
20100285577Isolation, Characterization and Propagation of Germline Stem Cells - Methods are provided for the isolation, characterization and propogation of germline cells stem cells from fetal and adult mammals. Additionally, isolated populations of germline cells having different phenotypes are disclosed wherein the subpopulations are capable of forming long-term cultures of multipotent or pluripotent cells or are capable of differentiating into mature germline cells and repopulating a sterile reproductive organ. The multipotent or pluripotent germline cells are also suitable for differentiation into tissue-specific somatic cells for therapeutic purposes.11-11-2010
20110136225BIOREACTOR, DEVICES, SYSTEMS AND METHODS - Disclosed are bioreactor devices, systems and methods. A bioreactor system can include one or more bioreactor modules that can be individually controllable and identifiable. A bioreactor module can be connected to one or more functional modules such as a pump module, a stimulation signal generation module, a motor module, a mechanical transmission module, a gas exchange module, a temperature module, a humidity module and/or a CO06-09-2011
20110136224MDA-7 PROTEINS AND METHODS OF USE THEREOF - This invention provides a method of generating a subtracted cDNA library of a cell comprising: a) generating a cDNA library of the cell; b) isolating double-stranded DNAs from the cDNA library; c) releasing the double-stranded cDNA inserts from the double-stranded DNAs; d) denaturing the isolated double-stranded cDNA inserts; e) hybridizing the denatured double-stranded cDNA inserts with a labelled single-stranded nucleic acid molecules which are to be subtracted from the cDNA library; and f) separating the hybridized labeled single-stranded nucleic acid molecule from the double-stranded cDNA inserts, thereby generating a subtracted cDNA library of a cell. This invention also provides different uses of the subtracted library.06-09-2011
20110076761RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS - The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.03-31-2011
20100323438GAS AND LIQUID TISSUE CULTURE INTERFACE - An apparatus and method is described for culturing and conditioning cells on a sample. The apparatus includes a fluid delivery system that transmits gas to a first surface of a sample and transmits liquid to an opposite surface of the sample without transmitting liquid onto the first surface. Further, while culturing cells on the sample, the apparatus enables a constant or variable tension and shear stress applied to the sample. The apparatus may thus, for example, be used to culture cells on an external surface of a tissue construct with air and culture cells underneath the tissue construct with a cell growth media. The fluid delivery system may alternatively transmit liquid cell growth media underneath and on the sides of the tissue construct without flowing onto a designated external surface of the tissue construct. In this manner, cells may be cultured on the tissue construct while stretching and relaxing the tissue and further simulating a dissimilar environment on opposite surfaces of the tissue construct.12-23-2010
20100330668Interaction Between the VHL Tumour Suppressor and Hypoxia Inducible Factor, and Assay Methods Relating Thereto - The invention relates to the finding that the VHL tumour suppressor protein regulates hypoxia inducible factor α subunits, by targeting HIF α for destruction in normoxic, but not hypoxic cells. The invention provides assays for modulators of this interaction, and peptides based upon HIF α subunit sequences which may modulate this interaction.12-30-2010
20110136222ACTUATORS FOR CULTURING AND HARVESTING CELLS - Actuator units, arrangements of actuator units and methods for manufacturing and using actuator units are provided. The actuator includes a core having a shell at least partially surrounding the core. The core is able to be stimulated to expand through at least one opening of the shell to provide a lifting action. This lifting action can be applied to harvest target cells.06-09-2011
20110076760Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays - This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).03-31-2011
20100233802CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.09-16-2010
20100167392FACTOR VIII COMPOSITIONS AND METHODS - The present invention provides methods of increasing the half-life and/or specific activity of factor VIII. More specifically, the invention provides methods of increasing the half-life and/or specific activity of factor VIII by substituting one or more amino acids in the A2 domain. It further provides methods for producing such factor VIII mutants. The invention also provides polynucleotides encoding the mutant factor VIII, and methods of treating hemophilia using the polypeptides and polynucleotides of the invention.07-01-2010
20090203123Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof - The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.08-13-2009
20090203130MULTIPOTENT ADULT STEM CELLS AND METHODS FOR ISOLATION - The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.08-13-2009
20090203127Nematode Fatty Acid Desaturase-Like Sequences - Nucleic acid molecules from nematodes encoding fatty acid desaturase polypeptides are described. Fatty acid desaturase-like polypeptide sequences are also provided, as arc vectors, host cells, and recombinant methods for production of fatty acid desaturase-like nucleotides and polypeptides. Also described are screening methods for identifying inhibitors and/or activators of fatty acid desaturase-like polypeptides, as well as methods for antibody production.08-13-2009
20090203126CELL CULTURE ARRAY SYSTEM FOR AUTOMATED ASSAYS AND METHODS OF OPERATION AND MANUFACTURE THEREOF - A number of novel improved microfluidic configurations and systems and methods of manufacture and operation. In one embodiment, three wells are used for independent cell culture systems in a cell culture array. In a second aspect, artificial sinusoids with artificial epithelial barriers are provided with just one (optionally shared or multiplexed) fluidic inlet and one (optionally shared or multiplexed) fluidic output, where the medium output also functions as a cellular input. A pneumatic cell loader combined with other components provides a fully automated cell culture system. Magnetic alignment of plate molds provides advantages and ease of molded manufacture.08-13-2009
20090176303Method and apparatus for propagating benthic marine invertebrates - An apparatus for propagating benthic marine invertebrates in water. The apparatus comprises (a) a culture cell, (b) a sedimentation chamber in fluid connection with the culture cell, and (c) a pump in fluid connection with the culture cell and with the sedimentation chamber capable of pumping water from the sedimentation chamber to the culture cell. Also disclosed is a method for propagating benthic marine invertebrates comprising culturing the invertebrates in a water environment in the apparatus.07-09-2009
20090176302Modified Mite Allergen and Pharmaceutical uses Thereof - The present invention provides a modified 07-09-2009
20100190246METHOD FOR PREPARING BIOLOGICAL TISSUE - This invention provides a method for obtaining biological tissue having a three-dimensional structure of interest. The method of the invention comprises: adding a cell-containing culture solution to a culture vessel having an inner bottom surface, which is non-cell adhesive and comprises a concave-convex pattern provided thereon; performing cell culture under conditions in which intercellular adhesion takes place while centrifugal or magnetic force toward the inner bottom surface is applied to the cells that were added to the culture vessel to form tissue via intercellular adhesion; and detaching and collecting the resulting tissue from the inner bottom surface at the end in order to obtain tissue having a three-dimensional configuration using a concave-convex pattern as a template.07-29-2010
20100028995Tetranectin Trimerizing Polypeptides - Tetranectin trimerizing polypeptides and fusion proteins including the polypeptides and therapeutic polypeptides and proteins. Trimeric complexes of the polypeptides and fusion proteins. Pharmaceutical compositions of the polypeptides, fusion proteins and the trimeric complexes.02-04-2010
20100028994NANOPARTICLE FABRICATION METHODS, SYSTEMS, AND MATERIALS FOR FABRICATING ARTIFICIAL RED BLOOD CELLS - A plurality of artificial red blood cell particles includes each particle of the plurality being substantially monodisperse and each particle having a largest common linear dimension of about 5 μm to about 10 μm. The particles can also have a modulus configured such that a particle of the plurality of particles can pass through a tube having an inner diameter of less than about 3 μm.02-04-2010
20080206863Embryonic stem cells capable of differentiating into desired cells lines - An embryonic stem cell which may be induced to differentiate homogeneously into a desired primary cell line. The embryonic stem cell may be engineered with DNA, which encodes a protein or polypeptide which promotes differentiation of the stem cell into a specific cell line, such as, for example, a neuronal cell line, a muscle cell line, or a hematopoietic cell line. The DNA may encode a transcription factor found in the particular cell line. In another alternative, a desired cell line is produced from embryonic stem cells by culturing embryonic stem cells under conditions which provide for a three-dimensional network of embryonic stem cells, and then stimulating embryonic stem cells with an agent, such as retinoic acid, or dimethylsulfoxide, which promotes differentiation of the embryonic stem cells into the desired cell line, such as, for example, a neuronal cell line, or a muscle cell line.08-28-2008
20110065176HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF - The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.03-17-2011
20100267128Compositions and method for use in isolation of nucleic acid molecules - The present invention relates generally to recombinant genetic technology. More particularly, the present invention relates to compositions and methods for use in selection and isolation of nucleic acid molecules. The invention further relates to methods for the preparation of individual nucleic acid molecules and populations of nucleic acid molecules, as well as nucleic acid molecules produced by these methods. The invention also relates to screening and/or selection methods for identifying and/or isolating nucleic acid molecules which have one or more common features (e.g., characteristics, activities, etc) and populations of nucleic acid molecules which share one or more features.10-21-2010
20100184209COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE - The present invention provides compositions and methods for inhibiting gene silencing by the RNAi pathway. The RNAi inhibitors of the invention have a reverse complement (RC) region to the target molecule of interest (e.g., miRNA) in association with at least one flanking region coupled to either at the 3′ or 5′ end of the RC region. The flanking regions can be single-stranded or can have one or more regions of double stranded nucleic acid with or without a hairpin loop. The RNAi inhibitors described herein can inhibit endogenous targets, including but not limited to microRNAs, or piRNAs, or can be used to inhibit the effects of exogenously introduced molecules, such as synthetic siRNAs, siRNAs expressed from vector constructs (e.g., viral expression systems), or siRNAs generated by enzymatic methods. Inhibition is specific, potent, prolonged, and can be performed on a single target or multiple targets simultaneously.07-22-2010
20100167390Novel Oligonucleotide and NF-kB Decoy Comprising the Same - A novel oligonucleotide useful as an NF-κB decoy having a higher binding ability to NF-κB than known NF-κB decoy as well as the medical uses thereof, is disclosed. The oligonucleotide of the invention has a base sequence having a consensus sequence and specific 5′-flanking and 3′-flanking sequences ligated to both ends of the consensus sequence, respectively. The NF-κB decoy is constituted by an oligonucleotide which is the above-described oligonucleotide of the invention and which is substantially double-stranded wherein the strands are complementary to each other.07-01-2010
20080311653Method and apparatus for regulating optimum flow of semen and separating motile sperms - The present invention discloses method and apparatus for regulating optimum flow of semen and separating motile sperms. The device consists of; a first cylindrical shape container, comprising a first external diameter, second external diameter, a thirds external diameter and a mesh, wherein said mesh is comprised of plurality of pores and attached to lower bottom of said first cylindrical shape container; a second cylindrical shape container comprising an internal diameter and an external diameter, wherein said second cylindrical shape container is closed ended at bottom, and embraces said first cylindrical shape container at said second external diameter of said first cylindrical shape container, thereby creating at least a first predetermined distance and at least a second predetermined distance, wherein said at least a first predetermined distance regulates air coming from said second cylindrical shape container, thereby regulating flow of semen and separating motile sperms coming through said mesh to said second cylindrical shape container.12-18-2008
20100028996RETROVIRAL VECTORS FOR DELIVERY OF INTERFERING RNA - Provided herein are retroviral vectors for delivering interfering RNA into cells.02-04-2010
20110306123METHOD FOR PREPARING BIOLOGICAL TISSUES FOR USE IN BIOLOGICAL PROSTHESES - A method of treating a biological tissue for biological prostheses includes steps of fixation of the biological tissue via a fixing solution including glutaraldehyde and detoxification of the fixed biological tissue via treatment with a detoxifying solution. The detoxification step includes one or both of eliminating phospholipids via treatment with an elimination solution and a treatment with a detoxifying solution. The elimination solution includes 1,2-octanediol and ethanol. The detoxifying solution includes taurine or homocysteic acid.12-15-2011
20110306124METHOD FOR DETOXIFYING A BIOLOGICAL TISSUE - Biological tissues may be prepared for use in biological prostheses. The biological tissue may be fixated with glutaraldehyde and may be subjected to successive treatment of the tissue with a solution containing taurine to neutralize excess aldehyde groups that remain free after fixation.12-15-2011
20100129902Replication Stable and RNase Resistant Chimeras of Pestivirus with Insertion in 3' Nontranslated Region (3'NTR) - The invention relates to the field of nucleic acid amplification, particularly to quality control materials for use in viral RNA assays. It specifically relates to the construction of a recombinant Pestivirus by the identification of a region in the 3′NTR of the viral RNA genome where additional sequence elements can be stably inserted. Chimeric Pestivirus with sequence insertions in the 3′ nontranslated region (3′NTR) of the viral RNA genome were stable in replication and capable of forming infectious, RNase resistant virus particles. This chimeric Pestivirus with a 3′NTR insertion can be utilized as a quality control material in analytical assays for RNA targets, including external, internal controls, quantitative standards in PCR and NAT nucleic acid assays.05-27-2010
20120301957Method and Apparatus for Collecting Biological Materials - A method and apparatus can separate and concentrate a selected component from a multi-component material. The multi-component material may include a whole sample such as adipose tissue, whole blood, or the like. The apparatus generally includes a moveable piston positioned within a separation container and a withdrawal tube that is operable to interact with a distal end of the collection container past the piston. Material can be withdrawn through the withdrawal tube.11-29-2012
20120301956Novel hydroxylated enantiomers of (-) 3a,6,6,9a-tetramethylperhydronaphtho[2,1-b]furan as perfuming agents derived from a fungal fermentation process - (−)3a,6,6,9a-tetramethylperhydronaphtho[2,1-b]furan (ambrox) is a strong aromatic compound used widely in a variety of perfumery applications and is highly prized for its musky odor. We report novel polar metabolites of (−)3a,6,6,9a-tetramethylperhydronaphtho[2,1-b]furan prepared by a novel process of microbial fermentation using a fungi, 11-29-2012
20120040452GLYPICAN-3 (GPC3)-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES USEFUL FOR HLA-A2-POSITIVE PATIENTS AND PHARMACEUTICAL COMPRISING THE SAME - It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): 02-16-2012
20120045828Apparatus for Magnetic Separation of Cells - Described here is an automated robotic device that isolates circulating tumor cells (CTCs) or other biological structures with extremely high purity. The device uses powerful magnetic rods covered in removable plastic sleeves. These rods sweep through blood samples, capturing, e.g., cancer cells labeled with antibodies linked to magnetically responsive particles such as superparamagnetic beads. Upon completion of the capturing protocol, the magnetic rods undergo several rounds of washing, thereby removing all contaminating blood cells. The captured target cells are released into a final capture solution by removing the magnetic rods from the sleeves. Additionally, cells captured by this device show no reduced viability when cultured after capture. Cells are captured in a state suitable for genetic analysis. Also disclosed are methods for single cell analysis. Being robotic allows the device to be operated with high throughput.02-23-2012
20090023205Method for the separation of living cells - The present in invention relates to a method for the separation of living cells from a mixture of dead and living cells which optionally can also possibly contain cell fragments.01-22-2009
20100035340VARIANTS OF HUMAN TASTE RECEPTOR GENES - Identified herein are different forms of bitter receptor genes that occur in different humans. These alleles are generated by numerous coding single nucleotide polymorphisms (cSNP's) that occur within the members of the T2R gene family. Some SNP's cause amino acid substitutions, while others introduce chain termination codons, rendering the allele non-functional. Differences in these genes are believed to have a large effect on those individuals' sense of bitter taste, such that these individuals perceive the taste of bitter substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define large groups and populations who perceive bitter tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level for the first time.02-11-2010
20120040453BIOREACTOR USING OXYGEN-CARRYING MOLECULES - The present invention relates to devices and bioreactors capable of delivering oxygen to a cell culture using oxygen-carrying molecules. The bioreactor comprises at least two chambers separated by an oxygen-permeable membrane. The oxygen-carrying molecules are chosen from extracellular hemoglobin isolated from worm belonging to Arenicoliolae family or Nereidiolae family.02-16-2012
20120156769Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.06-21-2012
20110318829CELL CULTURE CONTAINER AND CELL CULTURE METHOD - To provide a cell culture chamber and a cell culture method that are capable of effectively constructing an intercellular network in a culture space. A cell culture chamber (12-29-2011
20110318828KIT FOR PREPARATION OF ANTIGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES - The invention is intended to further improve the operability, economic efficiency and safety in the preparation of antigen-specific CTLs. The invention provides a preparation kit used for a method for preparing antigen-specific cytotoxic T lymphocytes, the method comprising: a first step for inducing antigen-specific cytotoxic T lymphocytes, wherein the components of the first step include a culture medium contained in an injection vessel, a hermetically sealed culture vessel, and the like; a second step for preparing an activated T cell for antigen presentation, wherein the components of the second step include a culture medium contained in an injection vessel, a hermetically sealed culture vessel, and the like, and a third step for proliferating antigen-specific cytotoxic T lymphocytes, wherein the components of the third step include a culture medium contained in an injection vessel, a hermetically sealed separation vessel, a hermetically sealed culture vessel, and the like.12-29-2011
20120208268MEDIA AND METHOD FOR CELL SEPARATION - The present invention relates to a separation media and a method for separation of cells from different cell sources, such as umbilical cord blood, using the separation media to obtain the desired cells, such as stem cells. The separation media has beads with a diameter of 200-500 μm and is provided with cell separation ligands. The cell specific ligands are preferably CD3 and CD19 for depletion of B and T cells and production of a stem cell rich product.08-16-2012
20090148940NOVEL FLUORESCENT PROTEINS FROM AEQUOREA COERULSCENS AND METHODS FOR USING SAME - The present invention provides nucleic acid compositions encoding a novel colorless GFP-like protein, acGFP, from 06-11-2009
20120208269METHOD OF ISOLATING DERMAL STEM CELLS - The invention provides a method of isolating dermal stem cells, having the steps of subjecting cells separated from the skin by enzyme treatment to suspension culture, and isolating cells positive for stem cell markers from the cultured cells.08-16-2012
20120045827SEPARATION OF ANTIGEN-SPECIFIC MEMORY B CELLS WITH A CONJUGATED BIOPOLYMER SURFACE - The present invention provides materials and methods for the isolation of immune cells. In one embodiment, the present invention provides a device for the isolation and separation of antigen-specific memory B cells. Immune cells will be separated by flowing the cells along a ligand-conjugated biopolymer surface. The ligand may be distributed in a concentration gradient along the z-axis of the biopolymer surface. Cells that display receptors specific for the ligands on the biopolymer will interact with the ligands and roll along the surface in the fashion of leukocyte rolling. Additive adhesive interactions will cause differential cell separation and eventual immobilization.02-23-2012
20120009671SYSTEM AND METHOD FOR MICROFLUIDIC CELL CULTURE - Microfluidic devices and methods for perfusing a cell with perfusion fluid are provided herein, wherein the gravitational forces acting on the cell to keep the cell at or near a retainer or a retaining position exceed the hydrodynamic forces acting on the cell to move it toward an outlet.01-12-2012
20120009670Use of Molecular Chaperones for the Enhanced Production of Secreted, Recombinant Proteins in Mammalian Cells - The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.01-12-2012
20110033925Cell Separation Method and Apparatus - Disclosed herein are apparatus and methods for isolating a fraction of interest from a physiological fluid sample.02-10-2011
20090203128Nogo-Receptors and Methods of Use - Disclosed are compositions relating to the Nogo receptor (NgR) family as well as fragments, chimeras, and variants thereof. The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the NgRs as well as uses thereof. Such uses include modulation neurite outgrowth in a subject and treatment of central nervous system disorders in a subject, as well as, methods of identifying and screening compounds that can be used for modulating neurite outgrowth in a subject or in treatment of central nervous system disorders in a subject.08-13-2009
20100216232MAMMAL DEDICATED CELL LINE - A mammal dedicated cell line is provided, which is a HepG2 hepatocellular carcinoma cell line (HepG2/NF-kB/Luc/sr39tk)1_18 obtained by co-transformation with NF-kB/Luc and NF-kB/sr39tk. Firstly, a successfully transformed pNF-kB/Luc HepG2 cell is obtained. Then, a dedicated cell line sensitive to TPA and MTX is generated by experimental screening Next, a plasmid construct carrying pNF-kB/sr39tk genome is introduced into the dedicated cell line by means of Superfect protocol. Finally, a HepG2 cell line co-expressing NF-kB/Luc and NF-kB/sr39tk is screened with G418 and ZEOCIN, and transformation result is confirmed by luminescence and radio activity. The (HepG2/NF-kB/Luc/sr39tk)1_18 obtained is suitable to screen drug for treating liver cancer and examine these cells by bioluminescence imaging and nuclear medicine imaging.08-26-2010
20100003749Enriched Pancreatic Stem Cell and Progenitor Cell, Populations, and Methods For Identifying, Isolating and Enriching For Such Populations - Enriched pancreatic stem and progenitor cell populations, and methods for identifying, isolating, and enriching for pancreatic stem cells using reagents that bind to cell surface markers are provided.01-07-2010
20120015434EXPANSION OF NK CELLS AND THERAPEUTIC USES THEREOF - The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells.01-19-2012
20120015433Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.01-19-2012
20120015432ISOLATED BITTER TASTE RECEPTOR POLYPEPTIDES - The claimed invention relates to the discovery of a specific human taste receptor in the T2R taste receptor family, hT2R61 that responds to particular bitter compounds The present invention further relates to the use of this receptor in assays for identifying ligands that modulate the activation of this taste receptor. These compounds may be used as additives and/or removed from foods, beverages and medicinals in order to modify (block) T2R-associated bitter taste. A preferred embodiment is the use of the identified compounds as additives in foods, beverages and medicinals for blocking bitter taste.01-19-2012
20100197008PROCESSING PARTICLE-CONTAINING SAMPLES - A microfluidic device includes an input port for inputting a particle-containing liquidic samples into the device, a retention member, and a pressure actuator. The retention member is in communication with the input port and is configured to spatially separate particles of the particle-containing liquidic sample from a first portion of the liquid of the particle containing fluidic sample. The pressure actuator recombines at least some of the separated particles with a subset of the first portion of the liquid separated from the particles. The device can also include a lysing chamber that receives the particles and liquid from the retention member. The lysing chamber thermally lyses the particles to release contents thereof.08-05-2010
20110165671PROCESS FOR PROVIDING AN ASSEMBLY OF CELL MICROCARRIERS - The present invention is related to a process for providing an assembly of cell microcarriers, comprising the steps of providing planar, two-dimensional objects having two sides (“flakes”), wherein these objects comprise a material which, upon application of an extrinsic stimulus, is transferred from the planar state into a rolled state, providing cells on one side of said flakes (“cell-bearing side”), transferring the flakes from the planar state into a rolled state (“cell wrap”) by application of said extrinsic stimulus, and coupling at least one type of binding agent to the flakes.07-07-2011
20110165672BUFFY COAT SEPARATOR FLOAT SYSTEM AND METHOD - A tube and float system for use in separation and axial expansion of the buffy coat includes a transparent or semi-transparent, flexible sample tube and a rigid separator float having a specific gravity intermediate that of red blood cells and plasma. The float includes a main body portion of reduced diameter to provide a clearance gap between the inner wall of the sample tube and the float. One or more protrusions on the main body portion serve to support the flexible tube. During centrifugation, the centrifugal force causes the diameter of the flexible tube to expand and permit density-based axial movement of the float in the tube. The float further includes a pressure relief system to alleviate pressure build up in the trapped red blood cell blood fraction below the float, thereby preventing red blood cells from being forced into the annular gap containing the buffy coat layers.07-07-2011
20110165670Ketoreductases and Uses Thereof - The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.07-07-2011
20110070642DEVICE AND METHOD FOR ISOLATING AND CULTIVATING LIVE CELLS ON A FILTER OR EXTRACTING THE GENETIC MATERIAL THEREOF - A device for isolating and cultivating live cells on a filter or for extracting the genetic material thereof includes: a filter holder (03-24-2011
20130011918METHODS FOR TELOMERE LENGTH AND GENOMIC DNA QUALITY CONTROL AND ANALYSIS IN PLURIPOTENT STEM CELLS - The generation of clinical-grade cell-based therapies from human embryonic stem cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells. Assays useful in identifying human embryonic stem cell lines and pluripotent cells resulting from the transcriptional reprogramming of somatic cells that have embryonic telomere length are described as well as quality control assays for screening genomic integrity in cells expanded and banked for therapeutic use, as well as assays to identify cells capable of abnormal immortalization,01-10-2013
20110091967SSX-4 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES - The invention describes HLA class II binding peptides encoded by the SSX-4 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD404-21-2011
20110065178DENDRITIC CELL POTENTIATION - A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are compositions containing the molecule and methods for using the compositions to treat or immunize individuals.03-17-2011
20110065183Methods and Apparatus for Isolating Platelets From Blood - A platelet collection device comprising a centrifugal spin-separator container with a cavity having a longitudinal inner surface. A float in the cavity has a base, a platelet collection surface above the base, an outer surface. The float density is below the density of erythrocytes and above the density of plasma. The platelet collection surface has a position on the float which places it below the level of platelets when the float is suspended in separated blood. During centrifugation, a layer of platelets or buffy coat collects closely adjacent the platelet collection surface. Movement of a float having a density greater than whole blood through the sedimenting erythrocytes releases entrapped platelets, increasing the platelet yield.03-17-2011
20110065181Methods and Apparatus for Segregation of Particles - The disclosure relates to an apparatus for segregating particles on the basis of their ability to flow through a stepped passageway. At least some of the particles are accommodated in a passage bounded by a first step, but at least some of the particles are unable to pass through a narrower passage bounded by a second step, resulting in segregation of the particles. The apparatus and methods described herein can be used to segregate particles of a wide variety of types. By way of example, they can be used to segregate fetal-like cells from a maternal blood sample such as maternal arterial blood.03-17-2011
20110065182Modified DNA Cleavage and Methods for Use - Compositions and methods are provided that relate to a modified DNA cleaving enzyme having at least 35% amino acid sequence identity with T7 Endo I. The modified enzyme includes two catalytic centers separated by a β-bridge where the β-bridge contains at least one mutation having an effect of altering enzyme cleavage activity compared to the unmodified enzyme. Activities associated with the modified DNA cleaving enzyme that can be modulated in different reaction conditions include at least one of: (a) non-sequence specific nicking activity; (b) cleaving the second strand of a duplex DNA at a preexisting nick site to produce a linear duplex with a single strand overhang; (c) non-sequence specific DNA cleavage; (d) cleaving DNA flanking a mismatch; and (e) cleavage at a cruciform structure in a DNA duplex.03-17-2011
20110065179TRANSGENE DELIVERING RETROVIRUS TARGETING COLLAGEN EXPOSED AT SITE OF TISSUE INJURY - A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.03-17-2011
20110065180EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGIC DISEASE - Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo.03-17-2011
20110065175Artificially synthesized peptide - A short synthetic vector peptide of 25 residues has been developed comprising hydrophobic domain and a novel, nuclear localization signal for efficient delivery, devoid of any cytotoxicity. Using the vector peptide, the oligonucleotide/peptide complexes got delivered evenly in cytoplasm and nucleus in less than an hour and finally localizing completely into nucleus in two hours and protein (antibody) to cytoplasm within 1 hour in both primary (chicken embryo fibroblast) cells and established mammalian cell line (Vero cells).03-17-2011
20110104800METHOD AND DEVICE FOR ISOLATING TISSUE CELLS FROM A LIQUID - A method and device for isolating tissue cells from a liquid is provided for integrating a mixture of the tissue cells and the liquid into a vacuum stream and isolating again from the vacuum stream in a tissue collection container (05-05-2011
20110104799Multifunctional Alleles - Nucleic acid constructs and methods for rendering modifications to a genome are provided, wherein the modifications comprise null alleles, conditional alleles and null alleles comprising COINs. Multifunctional alleles (MFA) are provided, as well as methods for making them, which afford the ability in a single targeting to introduce an allele that can be used to generate a null allele, a conditional allele, or an allele that is a null allele and that further includes a COIN. MFAs comprise pairs of cognate recombinase recognition sites, an actuating sequence and/or a drug selection cassette, and a nucleotide sequence of interest, and a COIN, wherein upon action of a recombinase a conditional allele with a COIN is formed. In a further embodiment, action of a second recombinase forms an allele that contains only a COIN in sense orientation. In a further embodiment, action by a third recombinase forms an allele that contains only the actuating sequence in sense orientation.05-05-2011
20110104798Compliant Surface Multi-Well Culture Plate - A multi-well plate can be loaded with a range of compliant substrates. Commerically-available assays can be used to test cellular responses across a plate with shear modulus from 50 to 51200 Pascals. Cells can be grown in the plates, and can be manipulated and analyzed. Hydrogels can be attached to the bottom of a well. The plates can support the attachment and growth of different cell types and can be compatible with standard 96-well and 384-well plate assays. The mechanical properties of the hydrogels can be reproducible and stable to increase the shelf life of the substrate. The hydrogel can be compatible with growth of a variety of cell types, various attachment ligands such as collagen I, collagen IV, fibronectin, vitronectin, laminin, or RGD peptides and can be coupled to the gel surface.05-05-2011
20120164724NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM - The invention relates to a novel aminotransferase, DNA encoding the enzyme, a recombinant vector into which the DNA has been introduced, and a transformant into which the vector has been introduced. Further, the invention also relates to a method for producing an optically active amino compound utilizing the enzyme or transformant. The aminotransferase of the invention has an ability of efficiently converting a ketone compound, particularly a cyclic ketone compound to an optically active amino compound. According to the invention, a method for efficiently producing an optically active amino compound, particularly an optically active cyclic amino compound is provided.06-28-2012
20100093077EXTRACELLULAR MATRIX COMPONENTS FOR EXPANSION OR DIFFERENTIATION OF HEPATIC PROGENITORS - A method is provided of propagating hepatic progenitors in vitro on or in one or multiple extracellular matrix components found in the stem cell compartment or niche of liver. A container for the propagation of the progenitors and comprising culture dishes, bioreactors, or lab chips.04-15-2010
20100093078SEPARATING DEVICE, AN ALGAE CULTURE PHOTOBIOREACTOR, AND METHODS OF USING THEM - The invention provides a device for separating a first entity and a second entity by flowing them downwardly in an inclined settling chamber. Each entity has its own outlet located at approximately the lowest end of the inclined settling chamber. The device may be used in industrial fields such as pharmaceutics, biologics, and biofuels, for the purposes of large-scale growth and separation of algae biomass, bacteria and yeast cultures; algae metabolite production; and cell separation, among others. The invention exhibits technical merits such as effective particle separation or concentration capacity, robust structure, easy operation, cost-effective manufacturability, disposability, and high productivity in e.g. perfusion photobioreactor systems.04-15-2010
20120164725DEEPWELL PLATE SYSTEM WITH LID - The present invention relates to a deepwell plate system, comprising a deepwell plate and a lid system which can be detachably fitted to the deepwell plate by snap- or clamp-fastening means so as to tightly seal the deepwell plate and to a method for the cultivation of cells within the deepwell plate system according to the present inven-tion.06-28-2012
20120231538LIPOPHILIC DYE-BASED FRET ASSAYS FOR CLOSTRIDIAL TOXIN ACTIVITY - Compositions useful for detecting Clostridial toxin activity comprising a cell that comprises a membrane-associated Clostridial toxin substrate comprising a first member of a fluorescence resonance energy transfer pair; and a Clostridial toxin recognition sequence including a cleavage site; and a membrane-associated second member of the FRET pair and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.09-13-2012
20100210012PURIFIED MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS - CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.08-19-2010
20120171764METHOD OF CELL CULTURES AND DEVICE FOR IMPLEMENTING IT - The invention generally provides a cell culture vessel having at least one first zone and at least one second zone, wherein the first zone is a transfer zone for a culture medium which essentially contains no cells and the second zone is a cell culture zone. The invention further includes methods utilizing the cell culture vessel.07-05-2012
20120171763DISSOCIATION METHOD AND DISSOCIATION AGENT FOR AVIDIN AND BIOTIN DERIVATIVES - A method for dissociating avidin or streptavidin efficiently from a biotin derivative, thereby making it possible to isolate a target material efficiently under a mild condition in a short period, and a dissociation agent for use thereof, are provided.07-05-2012
20120214229Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.08-23-2012
20120135516ARTIFICIAL ANTIBODY POLYPEPTIDES - A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, k05-31-2012
20120135517SYNTHETIC GENES AND GENETIC CONSTRUCTS - The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.05-31-2012
20100330669FVII OR FVIIA VARIANTS - Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237, or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to rhFVIIa.12-30-2010
20100173407INHIBITION OF GENE EXPRESSION - There is provided a method of inhibiting gene expression by locating a 5′-5 donor splicing site sequence in the 3′ UTR of a gene or within coding sequence containing the stop codon of a gene. Stability of homologous mRNA in trans is also adversely affected leading to a reduction in expression. A polynucleotide containing a 5′-donor splicing site sequence in either coding sequence containing the stop codon or the 3′ UTR is also provided and in one embodiment is in the form of a vector. The 5′-donor splicing site sequence can be present in multiple copies, for example as a tandem repeat. In one embodiment the 5-donor splicing site sequence has the sequence 5′-MAGGTRAGTA-3′ where M is A or C and R is A or G.07-08-2010
20100173406VIRUS MEDIATED CYTOPLASMIC EXPRESSION OF DNA VACCINES - The present invention relates generally to methods, systems, and compositions for cytoplasmic delivery and expression of DNA vaccines. The present invention further relates to methods, systems, and compositions for expressing an immune response modulator in an animal.07-08-2010
20100173408Receptor-based interaction trap - Described is a recombinant receptor comprising an extracellular ligand-binding domain and a cytoplasmic domain that comprises a heterologous bait polypeptide. The recombinant receptor is activated by binding of a ligand to the ligand-binding domain and by binding of a prey polypeptide to the heterologous bait peptide. The invention also discloses a method for detecting compound-compound binding using the recombinant receptor.07-08-2010
20120252116Fluid Flow Device Containing Nanotubes and Method for Cell Trafficking Using Same - The present invention relates to device and method for cell trafficking. In particular, the invention relates to a fluid flow device in which the flow surface has nanotubes immobilized thereon. The nanotubes have molecules on their outer surface, which support cell rolling. Also provided is a method for separation of a cell type from a mixture of different cell types or from a fluid based on the differential rolling property of the cell type on the flow surface.10-04-2012
20120077267DEVICE AND METHOD OF SEPARATING CELLS BY USING MAGNETIC FORCE - A cell separation device includes a channel or chamber in which a sample flows or moves, the sample including target cells marked with magnetic particles, and non-target cells, and a magnet which generates a magnetic first force in a first direction with respect to the sample within the channel or chamber. The channel or chamber of the cell separation device is applied with a second force in a second direction opposite to the first direction of the magnetic force. According to the cell separation device and a method of separating cells, the target cells move in the first direction by the magnetic force, and the non-target cells move in the second direction by the second force, by simultaneously applying the magnetic force and the second force in opposing directions, thereby separating the target cells from the non-target cells.03-29-2012
20120171762Stem and progenitor cell compositions recovered from bone marrow or cord blood; system and method for preparation thereof - The invention includes compositions of stem and progenitor cells recovered from bone marrow or cord blood containing most of the viable CD34+ cells and substantially depleted of red blood cells resident in the original sample, without any xenobiotic additives to aid cell separation. The invention also includes a system and method for preparing the compositions. The system includes a bag set and a processing device, which utilizes an optical sensor, microcontroller, servo motor, accelerometer, load cell, and battery. The system and method utilize centrifugation to stratify the cells into layers and then separate and transfer the stem cells into a stem cell bag. The processing device's microcontroller receives input from the device's accelerometer, load cell and optical sensor to direct the metering valve in the bag set to open and close to permit the transfer of as many stems cells as possible with as few red cells as possible.07-05-2012
20080213884Vectors for tissue-specific replication - The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector, therefore, a target tissue can be selectively treated.09-04-2008
20100273256Human Potassium Channel Genes - Methods for isolating K+Hnov genes are provided. The K+Hnov nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.10-28-2010
20100009439ANTI-IGF-I RECEPTOR ANTIBODIES, DNAs, VECTORS, HOST CELLS AND GENETIC CONSTRUCTS - DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.01-14-2010
20100009437Isolated proteins MAGE-4 and MAGE-41 - The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.01-14-2010
20100285578Nucleic Acid Purification - The inventive self-contained apparatus for isolating nucleic acid, cell lysates and cell suspensions from unprocessed samples apparatus, to be used with an instrument, comprises at least one input, and: (i) a macrofluidic component, comprising a chamber for receiving said unprocessed sample from a collection device and at least one filled liquid purification reagent storage reservoir; and (ii) a microfluidic component in communication with said macrofluidic component via at least one microfluidic element, said microfluidic component further comprising at least one nucleic acid purification matrix; and (iii) a drive mechanism on said instrument for driving said liquid purification reagent, through said microfluidic element and said nucleic acid purification matrix, wherein the only inputs to said apparatus are via said chamber and said drive mechanism.11-11-2010
20100291675IgM-MEDIATED RECEPTOR CLUSTERING AND CELL MODULATION - Materials and methods for using multivalent molecules (e.g., antibodies) to modulate cellular function. A molecule can be targeted to a particular type of cell, either through direct binding to an epitope on the surface of the cell, or through a linker that recognizes both the multivalent molecule and a marker on the cell surface.11-18-2010
20090209033Immortalized hepatocyte cell line secreting modified insulin with glucose sensitivity - The present invention provides a cell line which can be substituted for β cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.08-20-2009
20100003750MAKING ENCODED GHOST CELLS FOR MULTIPLEXED DETECTION OF ANTI-RED CELL ALLOANTIBODIES - Disclosed are methods for detecting antibody in a sample, where the antibody targets an antigen expressed by red blood cells or red blood cell ghosts. Rather than detecting the binding events between a particular antigen antibody pair (as in traditional agglutination based assays) the methods herein allow for multiplexed detection of clinically important allo-immune antibodies to blood group antigens. Specifically the method involves generating fluorescently encoded red blood cells or red blood cell ghosts with known antigen presentation and using them to detect the presence of antibody in serum/plasma with a fluorescent sandwich type immunoassay. The assay results can be read using flow cytometric or fluorescent microscope based imaging techniques.01-07-2010
20100291674DISPOSABLE BIOREACTOR, KIT FOR THE SAME AND METHOD FOR ITS PRODUCTION - The present invention discloses a disposable bioreactor, consisting of a container and a cap, which is connectable to the same and cannot be detached without destruction. For this purpose, the cap comprises a retaining structure with a plurality of locking arms running in the lateral direction, while the locking arms are adapted to be resiliently shortened in the longitudinal direction and to be locked vertically to the longitudinal direction in the container by way of a retaining surface.11-18-2010
20100291673ALTERNATIVE EXPORT PATHWAYS FOR VECTOR EXPRESSED RNA INTERFERENCE - The present invention is directed to nucleic acid molecules containing a loop sequence designed to circumvent exportin-5 mediated export, and methods using these novel molecules.11-18-2010
20100291672REAGENT FOR INTRODUCTION OF PROTEIN OR GENE - The present invention provides a reagent for introducing a protein or gene into a cell. The reagent of the present invention is, for example, a reagent for introducing a protein or gene into a cell, which comprises a composition comprising a cationic amino acid type lipid represented by the following formula (I)-1:11-18-2010
20120258530Novel Therapeutical Tools and Methods for Treating Blindness - The present inventions relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.10-11-2012
20120258532DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER - The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug-resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.10-11-2012
20120258531SYSTEMS AND METHODS FOR HARVESTING TARGET PARTICLES OF A SUSPENSION - Tube and float systems and methods for isolating, enumerating, and harvesting target materials of a suspension are described. In one aspect, a tube and float system includes a filter embedded in a tube cap. The filter enables the passage of fluids but prevents the passage of the target materials. The tube and float system can be used to isolate and enumerate the target materials by centrifuging the tube and float system with the suspension to trap the target materials between the float and inner wall of the tube. Fluids above and below the float are poured off and a second fluid can be introduced to the tube to re-suspend the trapped target material. The second fluid can be poured through the filter in the cap to trap the target material against the filter. The target material can be enumerated and analyzed.10-11-2012
20110124102Rage Fusion Proteins And Methods Of Use - Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin C05-26-2011
20120231540Non-Simian Cells for Growth of Porcine Reproductive and Respiratory Syndrome (PRRS) Virus - Disclosed are compositions and methods relating to growth of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) using non-simian cells. In a particular example, porcine alveolar macrophage cells are described as having a capability of supporting infectivity and reproduction by PRRSV. Cells and cell lines of the invention are disclosed in connection with applications relating to PRRS disease, including vaccine technologies.09-13-2012
20120231539Replication Stable and RNase Resistant Chimeras of Pestivirus with Insertion in 3' Nontranslated Region (3'NTR) - The invention relates to the field of nucleic acid amplification, particularly to quality control materials for use in viral RNA assays. It specifically relates to the construction of a recombinant Pestivirus by the identification of a region in the 3′NTR of the viral RNA genome where additional sequence elements can be stably inserted. Chimeric Pestivirus with sequence insertions in the 3′ nontranslated region (3′NTR) of the viral RNA genome were stable in replication and capable of forming infectious, RNase resistant virus particles. This chimeric Pestivirus with a 3′NTR insertion can be utilized as a quality control material in analytical assays for RNA targets, including external, internal controls, quantitative standards in PCR and NAT nucleic acid assays.09-13-2012
20120322145THREE-DIMENSIONAL CELL ADHESION MATRIX - The present invention provides a cell adhesion matrix having poly(vinyl alcohol) chains crosslinked via carboxy phenyl boronic acid crosslinkers. The cell adhesion matrix can also include a molecular recognition element bound to the poly(vinyl alcohol) chains via a carboxy phenyl boronic acid group, as well as including cells. The present invention also provides a method for making and de-gelling the cell adhesion matrix.12-20-2012
20110045585Kit for fluorometric analysis - Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3′-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.02-24-2011
20120270312DEVICE AND METHOD FOR BIOLOGICAL SAMPLE PURIFICATION AND ENRICHMENT - A device for sample purification and enrichment comprising a filtration unit having a filter and an agitator, wherein suction draws a sample across the filter and a back wash flushes materials collected in the filter. The amount of collected material in the filter is determined by a pressure measurer controlling the suction and back wash.10-25-2012
20100203629Cytoplasmic BKca Channel Intron-Containing mRNAs Contribute to the Intrinsic Excitability of Hippocampal Neurons - The invention relates to a method of modulating neuronal function by modulating the cytoplasmic level in a neuron of an intron-containing mRNA. The methods are useful in diagnostic, research and therapeutic applications.08-12-2010
20110236967PROMISCUOUS HER-2/NEU CD4 T CELL EPITOPES - The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides.09-29-2011
20110236966SINGLE LENTIVIRAL VECTOR SYSTEM FOR INDUCED PLURIPOTENT (IPS) STEM CELLS DERIVATION - The present invention is based on the discovery that a single lentiviral vector expressing multiple individual transcription factor proteins from a single multi-cistronic mRNA can reprogram a fibroblast cell to a stem cell-like cell. These reprogrammed induced pluripotent stem (iPS) cells are pluripotent. Additions of the Cre-LoxP sequences into the single lentiviral vector facilitate excision of the vector after reprogramming in achieved. Addition of a maker gene into the single lentiviral vector facilitates detection of the presence of the vector in an iPS. The invention provides compositions and methods of producing iPS cells using a single multi-cistronic lentiviral vector.09-29-2011
20120094376Engineered Extracellular Matrices Control Stem Cell Behavior - A composition for culturing stem cells is provided. The composition comprises an engineered purified collagen based matrix that has been formed under controlled conditions to have the desired microstructure and mechanical properties. The engineered purified collagen based matrix compositions of the present invention can be used alone or in combination with cells as a tissue graft construct to enhance the repair of damaged or diseased tissues.04-19-2012
20120288931METHODS FOR TREATING CANCERS AND PATHOGEN INFECTIONS USING ANTIGEN-PRESENTING CELLS LOADED WITH RNA - Disclosed are cells and methods for treating or preventing tumor formation or infections with pathogens in a patient. The cells of the invention are antigen-presenting cells (e.g., dendritic cells or macrophage) that have been loaded with RNA derived from tumors or pathogens. By administering the RNA-loaded antigen-presenting cells to a patient, tumor formation or pathogen infections can be treated or prevented. Alternatively, the RNA-loaded cells can be used as stimulator cells in the ex vivo expansion of CTL. Such CTL can then be used in a variation of conventional adoptive immunotherapy techniques.11-15-2012
20120100605DEVICE FOR CULTIVATING CELLS AND/OR MICROORGANISMS - A reactor is designed as a disposable element, a container receives the reactor, and a device comprises a reactor. A drive unit of the device generates a rotating-oscillating motion of the reactor, and the device is utilized for cultivating cells and/or microorganisms.04-26-2012
20120100604METHODS AND COMPOSITIONS FOR GENERATING SELF ATTENUATING GENETIC CIRCUITRY - The invention provides compositions and methods for engineering self-attenuating circuitry in a cell that provides an optimal homeostasis between TGF-β/pSmad and Notch signaling to produce the long-term restoration of tissue regenerative potential and repair.04-26-2012
20120142090Protein Expression System - The present invention relates to a method of producing a target protein, which method comprises expressing said protein in a host cell which contains a nucleic acid molecule which encodes a chimeric protein, said chimeric protein comprising a signal peptide from a non-mammalian bulk-secreted protein and said target protein; nucleic acids, vectors, host cells and kits for carrying out the method are also described.06-07-2012
20100167391GROWTH FACTOR HOMOLOG ZVEGF3 - Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.07-01-2010
20100129904RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS - This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.05-27-2010
20100129903PITX3 EXPRESSION PROMOTERS - Isolated polynucleotides comprising a PITX3 promoter are provided, where a PITX3 regulatory element is operably joined to a PITX3 basal promoter utilizing a non-native spacing between the promoter and regulatory elements. The promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.05-27-2010
20120149100CARDIOMYOCYTE CELL POPULATIONS - The present invention provides methods for inducing the differentiation of cardiac progenitor cells and cell populations produced by the methods of the invention. The invention further provides a method of screening for agents that affect cardiomyocytes, and a method of cardiomyocyte replacement therapy.06-14-2012
20120149098EXTRACTION OF PROCESS FOR MESENCHYMAL STROMAL STEM CELLS - Mesenchymal stromal stem cells are obtained starting with a biopsy sample from the iliac crest of the pelvis that is fragmented with surgical forceps in a saline solution and the saline solution containing the pulverised biopsy sample is then subjected to centrifugation, so to obtain mesenchymal stromal stem cells. The mesenchymal stromal stem cells are then selected by adhesion.06-14-2012
20110159584METHOD OF LOADING AND DISTRIBUTING CELLS IN A BIOREACTOR OF A CELL EXPANSION SYSTEM - A method of distributing a plurality of cells in a bioreactor of a cell expansion system includes manipulating an orientation of the bioreactor such that a net impulse due to gravity acting on the plurality cells in the bioreactor is reduced. One method includes (a) rotating the bioreactor at an angular velocity ω about an axis of rotation and through an angular displacement θ, the bioreactor rotating from a first orientation to a second orientation; (b) holding the bioreactor still at the second orientation for a first period of time t06-30-2011
20130023045INDUCED HEPATIC STEM CELL AND PROCESS FOR PRODUCTION THEREOF, AND APPLICATIONS OF THE CELL - The present invention relates to an induced hepatic stem cell defined as follows, a process for production thereof, and applications of the cell, which are useful in safety tests, toxicity tests, metabolism tests, drug interaction tests, antiviral activity tests, screening tests for pharmaceuticals such as hyperlipidemic therapeutics, hypertension therapeutics, low-molecular weight compound medicaments, and antibody medicaments, screening for targets in drug discovery, preparation of animal models, production of hepatocyte-produced proteins, and in regenerative medicine. The induced hepatic stem cell of the present invention is characterized by at least satisfying the following requirements (1)-(3): (1) it expresses at least 15 genes as selected from the group of the genes which are marker genes for an embryonic stem cell; (2) it has properties of a hepatocyte; and (3) it can be subjected to expansion culture or passage culture for at least 3 days.01-24-2013
20130023046MULTIPOTENT ADULT STEM CELL POPULATION - The present invention relates to the discovery of a population of non-germ adult stem cells that can be found in tissue from non-embryonic mammals, including at least mouse, rat, pig and human. These adult stem cells, which are present within the post-natal individual at all ages from infancy to senescence have a phenotype and developmental potential that is different from stem cell types, embryonic and adult, that have so far been described.01-24-2013
20080248565ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES - Systems and methods are provided for producing a protein of interest that is typically not amenable to expression in soluble form in in vitro expression systems. In some aspects, the invention provides methods of synthesizing proteins using in vitro protein synthesis systems that include a scaffold protein such as apolipoprotein or an amphipathic alpha helix containing (“AAHC”) protein, in which higher yields of soluble protein are produced than in the absence of the scaffold protein. The scaffold proteins may be provided in an in vitro protein synthesis system associated with lipid or not associated with lipid. The scaffold protein may be provided as a protein per se or may be encoded by a nucleic acid template and co-expressed with the protein of interest. The invention also provides compositions and kits for synthesis of proteins in soluble form, in which the compositions and kits include cell extracts for protein expression and isolation.10-09-2008
20080233637MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS - The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MRT-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.09-25-2008
20080227193Nematode Fatty Acid Desaturase-Like Sequences - Nucleic acid molecules from nematodes encoding fatty acid desaturase polypeptides are described. Fatty acid desaturase-like polypeptide sequences are also provided, as are vectors, host cells, and recombinant methods for production of fatty acid desaturase-like nucleotides and polypeptides. Also described are screening methods for identifying inhibitors and/or activators of fatty acid desaturase-like polypeptides, as well as methods for antibody production.09-18-2008
20080227192Nematode ATP Synthase Subunit E-Like Sequences - Nucleic acid molecules from nematodes encoding ATP synthase subunit E polypeptides are described. ATP synthase subunit E-like polypeptide sequences are also provided, as are vectors, host cells, and recombinant methods for production of ATP synthase subunit E-like nucleotides and polypeptides. Also described are screening methods for identifying inhibitors and/or activators, as well as methods for antibody production.09-18-2008
20130177977Systems and Devices for Restraining a Cell and Associated Methods - Systems, devices, and methods for restraining a biological structure are provided. In one example, a biological structure restraining device can include a barrier structure, an opening defined in the barrier structure, and at least two contact points positioned adjacent to the opening and oriented to contact the biological structure, wherein the barrier structure and the opening are structurally positioned to receive the cell at the contact points. In another aspect, the device can also include a biological structure manipulator having a structure operable to press the biological structure against the contact points. In yet another aspect, the device can further include a biological structure injector having a structure operable to be inserted through the opening and into the biological structure, wherein the biological structure manipulator is operable to maintain the biological structure against the contact points as the biological structure injector is inserted into the biological structure.07-11-2013
20110269228STORAGE UNIT FOR AT LEAST ONE DEVICE FOR IDENTIFYING ANIMALS AND/OR COLLECTING ANIMAL TISSUE, AND CORRESPONDING METHOD FOR IDENTIFYING OR COLLECTING TISSUE - A storage unit is disclosed for at least one animal identification and/or animal tissue collecting device, capable of storing said at least one identification and/or collecting device. In several embodiments, such a set includes at least one container containing a specific agent designed to be applied at least partially to at least one element of said identification and/or collecting device.11-03-2011
20130095564CELL SEPARATING APPARATUS AND CELL SEPARATING METHOD - A cancer cell separating apparatus includes: a flow channel including an antibody fixation area having antibodies which bind specifically to cancer cells fixed thereon, wherein the cancer cells and non-cancer cells are separated using a difference in velocity of movement between the cancer cells and the non-cancer cells in cell slurry introduced into the flow channel.04-18-2013
20130122583STERILIZATION PROCESS - The present invention relates to a process for sterilizing implantable biomaterials. In particular, the invention relates to a process for sterilizing collagen-containing implantable biomaterials and storage thereafter.05-16-2013
20130130371Lipoaspirate stem cell separation system and methods thereof - A system and method for isolating and separating lipoaspirate particles. The system includes a generally cylindrical container having a lid and a bottom wherein the container includes at least one input port positioned to permit a lipoaspirate fluid to enter the container above the bottom; and a source of a vacuum coupled to the container to provide a partial vacuum during use of the system.05-23-2013
20130143315SHEET-SHAPED CELL CULTURE DISSOCIATION SYSTEM AND METHOD - Disclosed is a system for dissociating a sheet-shaped cell culture into individual cells. The system, so configured as to minimize the amount of damage to cells when dissociating a sheet-shaped cell culture into individual cells, in one form includes: (i) a reaction unit that dissociates the sheet-shaped cell culture; (ii) a sensor unit that acquires information relating to a particle size distribution of cells inside the reaction unit; and (iii) an analysis unit that computes the particle size distribution of the cells from the information acquired by the sensor unit and determines and outputs a dissociation state.06-06-2013
20110212519COMPARTMENTALIZED DEVICE FOR CELL CULTURE, CELL PROCESSING AND SAMPLE DIALYSIS - A versatile compartmentalized cell culture device, with a selectively permeable membrane separating the compartments, provides many attributes relative to traditional devices. It can be configured for high-density cell culture, co-culture, and sample dialysis while rolling or standing still. It can also be configured for continuous movement of liquid between compartments. The wide combination of attributes not found in other membrane based cell culture and bioprocessing devices includes more cell capacity, more cell secreted product capacity, higher cell and product density, increased medium capacity, minimized use of exogenous growth factors, compatibility with standard cell culture equipment and protocols, increased scale up efficiency, capacity to function when rolling or standing still, capacity for perfusion without the need for pumps, and more efficient sample dialysis.09-01-2011
20080199955Tissue Infiltration Apparatus - A tissue infiltration apparatus (08-21-2008
20080199954METHODS FOR SORTING DIMORPHIC DAUGHTER CELLS - This invention relates to methods for distinguishing and sorting cells. In particular it includes methods for distinguishing and sorting post-mitotic and post-meiotic daughter cells into two classes according to differential cellular features. Labeling, tagging, or marking of the cells' chromatin proteins, RNA, or DNA may assist in distinguishing the daughter cells. In some embodiments, two cell classes may be studied and the cells' proteins, glycoproteins, and RNA may be identified and subset. Information from these subsets may then be used to distinguish and sort the two classes of cells from similar tissues according to protein, glycoprotein, and RNA makeup.08-21-2008
20080199953SYSTEM AND METHOD FOR FORMING A CONNECTIVE TISSUE CONSTRUCT - A system and method are provided for forming a connective tissue construct, such as a tendon construct, in vitro. A substrate is provided with at least two anchors secured thereto in spaced relationship. Fibroblast cells are provided on the substrate in the absence of a synthetic matrix, where at least some of the cells are in contact with the anchors. The cells are cultured in vitro under conditions to allow the cells to self-organize and become confluent between the anchors, where the anchors are receptive to the cells and allow the cells to attach thereto while permitting the cells to detach from the substrate to form a three-dimensional connective tissue construct.08-21-2008
20110223657TRP/HIS EXCHANGE AND KYNURENIN INDUCED TRP TRANSPORT - The present invention provides methods for detecting changes in tryptophan concentrations in a cell and methods for identifying agents that modulate cellular tryptophan concentrations. In particular, the present invention provides methods for detecting cellular exchange between tryptophan and kynurenine, and methods for identifying agents that modulate this exchange. The present invention also provides methods for treating a disease associated with immunosuppression in a subject in need thereof. In particular, the present invention is directed toward a method of treating a disease associated with immunosuppression comprising contacting the disease with an agent that modulates cellular Trp/kynurenine exchange. Furthermore, the present invention provides methods for identifying an agent that modulates an immunosuppression.09-15-2011
20110244564CYSTINE KNOT MOLECULES - The present invention relates generally to a molecular framework having a cyclic structure. More particularly, the present invention provides cyclic proteins and derivatives thereof in which particular turns and other elements of the molecular structure are held in defined orientations with respect to each other. The cyclic proteins of the present invention provide a molecular framework for the introduction of particular amino acids or heterologous amino acid sequences to facilitate the presentation of biological activities associated with these heterologous amino acid sequences. The molecular framework of the present invention may be naturally cyclic or may be a cyclized derivative of a linear molecular or may be a linear derivative of a cyclized molecule. The present invention contemplates the use of the molecular framework with or without particular ammo acids inserted or substituted thereon for the treatment of or prophylaxis of disease conditions in animals, mammals (including humans) and plants.10-06-2011
20110250679Methods and Compositions for High-Resolution Micropatterning for Cell Culture - Composite structures and methods for generating micropatterned materials suitable for use in cell culture applications are disclosed. The improvement of these compositions and methods over the prior art is based on the unexpected discovery that minor chemical modifications can be introduced to greatly enhance the adherence and/or stability of a cell-adhesive material. The micropatterned materials are inexpensive to manufacture, have long shelf-life, and are stable for prolonged periods of time under cell-culture conditions. Moreover, biologists can use these micropatterned substrates with the same ease as conventional cultureware and without the need for special sample preparation.10-13-2011
20120258529APPARATUS FOR SEPARATING TARGET MOLECULES AND METHOD OF SEPARATING TARGET MOLECULES BY USING THE SAME - An apparatus for separating target molecules includes a plurality of protruding portions on a first sidewall of a fluid channel to control a flow of a fluid containing the target molecules, and a fluid channel portion having a variable height for separating the target molecules depending on sizes of the target molecules.10-11-2012
20100311158DEVICE AND SYSTEM FOR CULTURING CELLS AND METHOD OF CULTURING CELLS USING THE SAME - The present invention provides a device for culturing cells. The device includes a well and a membrane. The well has an internal space and a membrane actuating control channel. The internal space has an inlet and an outlet. The membrane is provided between the membrane actuating control channel and the internal space such that the membrane actuating control channel is isolated from the internal space. The membrane is elastically varied in shape to form a three-dimensional cell culture space in the internal space.12-09-2010
20100317099Liquid Separation from Adipose Tissue - Extracting or removing at least a portion of liquid phase from a whole sample using a centrifugal force is disclosed. Centrifugal forces are used to apply pressure to a whole sample and drive a liquid phase through a passage region that can be perforated and/or porous and maintain a drier portion within a separation container. The whole sample can be dried, which includes a remaining sample where excess or a selected amount of liquid is removed. Direct access to the separation container or area can then be made to provide for an efficient withdrawal of the drier material from the separation container.12-16-2010
20100317098Compositions and Methods for Diagnosing and Treating Cancer - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.12-16-2010
20130157355ROCKABLE BIOCONTAINER - Biocontainers, as well as methods and platforms for rocking the biocontainers, are disclosed.06-20-2013
20120282688REACTOR SYSTEMS - This disclosure relates to equipment utilized to manufacture chemical agents, particularly biopharmaceuticals. In some embodiments, reactor systems comprising a mobile carriage assembly; a disposable reaction container removably attached to the carriage assembly; and, a carriage holder into which the mobile carriage assembly may be removably inserted are provided.11-08-2012
20110294207SPATIALLY-DEFINED MODIFICATION OF FRESH TISSUE USING COVALENT CHEMISTRY - Methods for modification of tissue using covalent chemistry. Tissue can be modified through direct alkylation, reduction followed by alkylation, or oxidation followed by condensation to covalently attach small organic molecules or appropriately modified proteins. The modification can be spatially limited to desired regions of the tissue surface.12-01-2011
20110306122Hanging Drop Plate - A hanging drop plate and a method of cultivating cells or of producing molecular aggregates in at least one liquid volume that adheres to a drop contact area of such a hanging drop plate. The hanging drop plate has a body with a first surface and a second surface that is essentially coplanar to the first surface. The second surface has a drop contact area for adherently receiving a liquid volume. The drop contact area is distinguished from a surrounding area by a relief structure that prevents spreading of the liquid volume on the second surface of the body. The body has at least one conduit that mouths into the drop contact area from the direction of the first surface of the body. A liquid volume is applied to the drop contact area through a communicating conduit. Cells and/or molecules can be introduced into this liquid volume.12-15-2011
20110312087BIOREACTOR FOR THE CULTIVATION OF MAMMALIAN CELLS - Large-scale bioreactors having at least two impellers, large-scale bioreactor systems and methods for the large-scale cultivation and propagation of mammalian cells using these bioreactors.12-22-2011
20130189773PRODUCTION OF HYPOTHIOCYANITE FROM HALOGENATED CELLS - Methods of producing antimicrobial compositions include reacting halogenated eukaryotic cells with thiocyanate to produce the antimicrobial compound hypothiocyanite.07-25-2013
20120021508Method and Device for Identification of Nucleated Red Blood Cells from a Maternal Blood Sample - A method for concentrating and isolating nucleated cells, such as a maternal and fetal nucleated red blood cells (NRBC's), in a maternal whole blood sample. The invention also provides methods and apparatus for preparing to analyze and analyzing the sample for identification of fetal genetic material as part of prenatal genetic testing. The invention also pertains to methods and apparatus for discriminating fetal nucleated red blood cells from maternal nucleated red blood cells obtained from a blood sample taken from a pregnant woman.01-26-2012
20120021507BIOREACTOR AND USES THEREOF - Disclosed are bioreactor systems and methods to transfer a gaseous composition into a liquid composition in a closed environment. Also disclosed are bioreactor systems and methods for high-density culture of microorganisms and stably culture of activated sludge.01-26-2012
20120028350BONE MARROW TARGETING PEPTIDES - A peptide for targeting bone marrow consists of about 5 to about 25 amino acids and includes an amino acid sequence that targets the peptide to bone marrow.02-02-2012
20120028349Sorting Chamber - A sorting chamber (02-02-2012
20130196427CANCER ANTIGEN PEPTIDES DERIVED FROM WT1 - The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding said peptide, CTL-inducers, and cancer vaccine comprising said peptide or polynucleotide.08-01-2013
20130196428Cells expressing Th1 characteristics and cytolytic properties - A novel cell type has been generated that has both Th1 characteristics and cytolytic activity. These Th1/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Th1 characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL activity is targeted toward diseased cells, not normal cells. The cytolytic activity of the Th1/killer cells is mediated by Granzyme B-Perforin mechanism and results in apoptotic death of diseased cells. Methods of producing and using these Th1/killer cells include isolating CD4+ cells from peripheral blood, activating the CD4+ T-cells to form Th1/killer cells and administering these Th1/killer cells with the cytolytic activity to a patient wherein the Th1/killer cells are allogeneic to the patient.08-01-2013
20130203160Transgenomic Mitochondria, Transmitochondrial Cells and Organisms, and Methods of Making and Using - This invention provides transgenomic mitochondria, transmitochondrial cells and organisms, and the materials and methods for making such mitochondria, cells and organisms.08-08-2013

Patent applications in class ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE

Patent applications in all subclasses ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE